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Abstract 
 
THERAPEUTIC EFFECTS OF HPLC-ISOLATED SUBFRACTIONS FROM 
ETHANOLIC MORINGA OLEIFERA LEAF EXTRACTS ON CANCER AND 
INFLAMMATORY DISEASES 
 
Jamison Ray Slate 
B.S., Appalachian State University 
 
 
Chairpersons:  Maryam Ahmed Ph.D. and Nathan Mowa Ph.D. 
 
 
 The nutrient-dense and medicinal plant, Moringa oleifera, has a variety of reported 
therapeutic applications, which makes it a popular nutraceutical on the natural product 
market. However, scientists have only recently started to verify the therapeutic potential of 
M. oleifera products. Previous studies in our labs have shown potent anti-inflammatory and 
anticancer effects associated with ethanolic M. oleifera whole-leaf extracts. To further 
investigate potential applications of these M. oleifera extracts, our current project uses high 
performance liquid chromatography (HPLC) to separate bioactive compounds from the 
whole extract into distinct subfractions. We hypothesized that these HPLC-isolated M. 
oleifera subfractions could exhibit therapeutic effects in a cancer microenvironment by 
decreasing cancer cell viability and attenuating inflammatory cytokine production. Our 
results indicated that several of the subfractions significantly decreased the viability of HeLa 
and SiHa cervical cancer cells in a dose and time dependent manner. Additionally, these 
subfractions decreased macrophage secretion of the pro-inflammatory cytokines, interleukin-
6 (IL-6) and tumor necrosis factor alpha (TNFα), in a lipopolysaccharide (LPS)-induced 
 v 
model of inflammation. Overall, these data indicate that chemical compounds in M. oleifera 
may be explored as an alternative treatment option for some cancers and inflammatory 
disorders. Further studies in our labs will seek to identify the bioactive compounds in our 
subfractions using time-of-flight mass spectrometry and other analytical techniques. 
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Chapter One 
1. Introduction 
 The nutrient-dense and medicinal plant, Moringa oleifera, has long been utilized by 
various tropical and subtropical countries for its reported therapeutic effects and health 
benefits (Abdull Razis et al., 2014). While M. oleifera is native to the sub-Himalayan regions 
of Asia (including parts of India, Pakistan, Bangladesh, and Afghanistan), it is now globally 
dispersed and considered to be indigenous to regions of Southeast Asia, Africa, and South 
America (Abdull Razis et al., 2014; Kasolo et al., 2010). There are at least 12 other species in 
the Moringa genus, but M. oleifera is by far the most widely cultivated species and goes by a 
plethora of regional names such as Mulangay, Marango, Benzolive, Drumstick tree (to 
describe its seed pods), Horseradish tree (to describe its root flavor), and the “miracle tree” 
(due to its bountiful nutritional, medicinal, and economical uses) (Abdull Razis et al., 2014; 
Melo et al., 2013). This so-called miracle tree has become a staple crop for many rural 
communities due to its fast growth, drought resistance, high-yield of edible matter (including 
roots, seed pods, flowers, and leaves), and its applications in phytomedicine (Abdull Razis et 
al., 2014; Melo et al., 2013). Since many of these rural communities are isolated from 
primary healthcare facilities, the phytomedicinal and nutritive properties of M. oleifera 
products are offered as reasonably priced alternatives to western medicines (Abdull Razis et 
al., 2014). Several of the reported uses for M. oleifera products include antiseptic 
applications, managing inflammatory diseases (like asthma and arthritis), treating microbial 
infections (i.e. bacterial, viral, and fungal), controlling diabetes, preventing cardiovascular 
disease, and even mitigating some types of cancer (Abdull Razis et al., 2014; Kasolo et al., 
2010). 
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1.1 Moringa oleifera’s Applications as a Natural Product 
Nutritional Benefits: 
 Generations of M. oleifera consumers have proclaimed the health benefits and 
applications of this medicinal plant; however, the scientific community has only recently 
started to investigate and verify some of these claims. One claim that has gained substantial 
backing from the scientific community states that consuming various parts of the plant (e.g. 
roots, leaves, flowers, or seeds) can provide bountiful nutritional benefits.  When this claim 
was tested, analytical chemists determined that M. oleifera leaf powder, or leaf dry matter 
(d.m.), can contain 25 times more iron than spinach, 17 times more calcium than milk, 15 
times more potassium than bananas, and 9 times more protein than yogurt (Jaroszewska et 
al., 2012). Additional chemical analysis has shown that M. oleifera leaf products contain 
significant quantities of essential micronutrients like iron (54.7 mg/kg d.m.), phosphorus 
(5,700 mg/kg d.m.), potassium (37,300 mg/kg d.m.), calcium (12,800 mg/kg d.m.), 
magnesium (9,600 mg/kg d.m.), manganese (25.5 mg/kg d.m.), and zinc (17.4 mg/kg d.m.) 
(Jaroszewska et al., 2012). It is also worth noting that many of these analyzed leaf products 
were very low in toxic heavy metals (like lead, nickel, or cadmium), and all previously listed 
micronutrients were present in concentrations deemed safe by the World Health Organization 
(Jaroszewska et al., 2012). 
 While numerous studies have reported large quantities of micronutrients to be found 
in M. oleifera leaves, other studies have shown that a variety of factors can impact the 
nutritive value of M. oleifera products (Jaroszewska et al., 2012). For example, the type of 
edible plant matter (flowers, seedpods, leaves, roots, etc.), the regional water and soil 
conditions, or even the preparation techniques (raw, cooked, dried, extracted, etc.) used to 
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produce M. oleifera products can significantly impact micronutrient concentrations (Kumssa 
et al., 2017; Jaroszewska et al., 2012). Most studies on M. oleifera nutrition only focus on the 
benefits that leaf products offer, but newer studies are looking at the nutritional benefits of 
the other edible plant parts. For instance, M. oleifera leaves are known to contain high levels 
of calcium (18,300 mg/kg d.m.) and moderate amounts of iron (202 mg/kg d.m.), while M. 
oleifera flowers contain lower amounts of calcium (3,650 mg/kg d.m.) but significantly 
higher amounts of iron (253 mg/kg d.m.) (Jaroszewska et al., 2012). It is also pertinent to 
consider the regional soil environments that M. oleifera products are grown in, as there is a 
significant positive correlation between soil elemental concentrations and the elemental 
concentrations in harvested plant matter (Kumssa et al., 2017). 
 As previously stated, the way M. oleifera products are prepared can greatly affect the 
nutritional value and bioactivity of the plant matter. While consuming fresh M. oleifera 
products may be optimal for managing micronutrient deficiencies, it is often more practical 
to dry and store the harvested plant matter for later use when fresh products are limited 
(Jaroszewska et al., 2012). Human micronutrient deficiencies in rural sub-Sahara African 
communities are known to spike in dry seasons, when nutrient-dense vegetables become 
scarce (Kumssa et al., 2017). However, there is a growing body of research that postulates 
increased production, consumption, and preservation of drought-resistant M. oleifera crops 
could stabilize these seasonal spikes in micronutrient deficiencies (Kumssa et al., 2017). 
While dried products may lose some of their bioactivity when stored for long periods of time, 
the general scientific consensus seems to indicate that drying leaf and other plant matter is an 
effective way to preserve most nutritional components and prevent spoilage due to microbial 
growth (Jaroszewska et al., 2012). 
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Antimicrobial Activity: 
 While performing chemical analyses on M. oleifera extracts, some researchers have 
observed potent antimicrobial effects associated with extracts prepared from the leaves, 
roots, bark, and seeds of the plant (Mangundayao and Yasurin, 2017; Ugwoke et al., 2017). 
One study found that a hydroethanolic leaf extract had stronger inhibitory capabilities than 
tetracycline (a common broad-spectrum antibiotic) on the following bacterial species: 
Pseudomonas aeruginosa, Shigella sonnei, Staphylococcus aureus, Bacillus cereus, Bacillus 
subtilis, Bacillus megaterium, and Sarcina lutea (Rahman et al., 2009). A similar study 
looked at the antimicrobial potential of hydromethanolic leaf and root extracts, and they 
found that it had comparable antibacterial effects to Gentamicin on Bacillus subtilis, 
Pseudomonas aeruginosa, Escherichia coli, and Salmonella typhi (Ugwoke et al., 2017). 
These bactericidal properties found in M. oleifera extracts are being investigated by 
biomedical and food-production researchers for the development of new antimicrobials 
(Mangundayao and Yasurin, 2017). Overuse of commercial antibiotics in these industries has 
led to the rise of drug resistant pathogens, and thus an ensuing need to develop alternative 
treatments to deal with these pathogenic threats to the general public and agricultural animals 
(Mangundayao and Yasurin, 2017).  
 The studies indicated previously have predominantly shown that M. oleifera leaf 
extracts have potent antibacterial effects, but more promising broad-spectrum antimicrobial 
effects have been observed from seed and husk extracts. Extracts made from M. oleifera 
seeds, pods, and husks encompass notable bacteriostatic, bactericidal, fungicidal, and water 
coagulative properties (Mangundayao and Yasurin, 2017; Arora and Onsare, 2014). In a 
recent study, one research group tested an organic M. oleifera husk extract against a variety 
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of bacterial species as well as a few fungal species; the results of their experiments showed 
that their extract had comparable microbicidal effects to Ciprofloxacin for tested bacterial 
strains and Amphotericin B for tested fungal strains (Arora and Onsare, 2014). These potent 
microbicidal effects were even observed on Methicillin-resistant Staphylococcus aureus 
(MRSA), which is known to be unaffected by many common antibiotics (Arora and Onsare, 
2014). These results further indicate that some M. oleifera extracts may have broad-spectrum 
antimicrobial activity, which could be developed into future nutraceuticals (Arora and 
Onsare, 2014).  
 While nutraceutical companies are looking to develop new M. oleifera products for 
the diverse pharmacological potential of seed and husk extracts, these extracts are already 
being used by rural communities to purify drinking water due to their antimicrobial activity 
(Araújo et al., 2013). Extracts made from the seeds and roots of M. oleifera are believed to 
clarify drinking water in these communities through two main mechanisms. First, these 
extracts contain compounds which can disrupt microbial membranes (Arora and Onsare, 
2014; Mangundayao and Yasurin, 2017). Second, lectins (proteins capable of binding 
carbohydrates) extracted from the plant material are able to flocculate contaminants and 
microbes in the water for removal in subsequent filtration (Araújo et al., 2013; Mangundayao 
and Yasurin, 2017). The combination of these two mechanisms has made M. oleifera a 
popular natural product to treat drinking water, and follow up studies have shown that these 
products are safe for human consumption in concentrations commonly used for water 
purification (Araújo et al., 2013). 
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Anti-inflammatory and Anticancer Properties: 
 One of the most common uses of M. oleifera products is treating acute and chronic 
inflammatory illnesses. This is due to the plant material containing potent 
immunomodulatory compounds. More specifically, leaf extracts that contain higher 
concentrations of phytochemicals, like phenols and flavonols, appear to have the most potent 
anti-inflammatory capabilities when tested in vitro and in vivo (Abdull Razis et al., 2014). 
Initial research with M. oleifera extracts has shown that bioactive compounds in the plant 
were able to reduce the secretion of pro-inflammatory cytokines by ubiquitous immune cells, 
like macrophages (Araújo et al., 2013). Interestingly, successive studies have shown that 
extracted compounds from M. oleifera can concurrently increase anti-inflammatory immune-
cell signaling while decreasing inflammatory signaling (Fard et al., 2015). Furthermore, 
researchers have shown that these bioactive compounds can modulate several different 
inflammatory pathways, like NF-κB and STAT, to achieve their efficacious results (Fard et 
al., 2015; Qin et al., 2017). 
 These immunomodulatory and anti-inflammatory properties of M. oleifera extracts 
have therapeutic potential for a plethora of diseases, many of which are chronic due to self-
perpetuating overactive immune responses. In fact, immunomodulatory natural products have 
recently been suggested as novel therapeutic options to treat some types of cancer, a 
classification of diseases in which inflammation has recently been specified as hallmark of 
tumor progression (Qin et al., 2017). While acute inflammation initially plays a role in tumor 
regression, it has been shown that chronic inflammation creates tumor microenvironments 
that can lead to compounding cellular mutations, initiate cancerous tumor growth, and 
increase metastatic capabilities of the tumor cells (Qin et al., 2017). Consequently, some 
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researchers have looked at the ability of anti-inflammatory compounds, like those found in 
M. oleifera extracts, to attenuate inflamed tumor environments and halt the progression of 
different types of cancer (Qin et al., 2017). 
 A large focus of my project has been exploring M. oleifera extracts as anticancer 
agents with tumoricidal activity. In addition to controlling inflammation in the tumor 
microenvironment, several studies have identified antiproliferative and apoptotic compounds 
in M. oleifera extracts; these anticancer compounds include phytochemicals, like quercetin 
and kaempferol, which have induced cancer cell apoptosis in previous in vitro experiments 
(Sreelatha et al., 2011). One such study found that an aqueous M. oleifera leaf extract was 
able to decrease cell viability of KB tumor cells in a dose-dependent manner upon 
application (Sreelatha et al., 2011). Further investigations from this laboratory group showed 
that the extract was inducing apoptosis, or programmed cell death (normally seen in healthy 
cells), in these cancerous cells (Sreelatha et al., 2011). 
 
1.2 Overview of Inflammation, Anti-Inflammatory Drugs, and Therapeutic Natural Products 
 Many of the communities that have traditionally consumed medicinal M. oleifera 
products are isolated from primary healthcare facilities (Abdull Razis et al., 2014). Therefore, 
people in these areas tend to heavily rely on phytomedicines, or nutraceuticals, to treat a 
variety of diseases and chronic conditions (Arulselvan et al., 2016; Abdull Razis et al., 2014). 
Chronic illnesses often disrupt homeostasis and can create imbalanced or overactive immune 
responses, so the immunomodulatory and anti-inflammatory properties of M. oleifera 
extracts are well suited to treating these conditions. Typically, anti-inflammatory extracts 
from M. oleifera are often more affordable, easier to access, and potentially less toxic for 
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prolonged use when compared to standard anti-inflammatory drugs (e.g. steroids) from 
primary healthcare facilities (Arulselvan et al., 2016). Subsequently, this has led to M. 
oleifera products becoming a staple on the natural product market and in drug discovery 
research facilities (Arulselvan et al., 2016; Abdull Razis et al., 2014). 
 Although inflammation is often thought of as problematic, it is an integral part of the 
immune system’s defense response and can be beneficial. When properly regulated, 
inflammation functions to protect the body from pathogens and foreign objects by localizing 
damage and alerting the immune system into action (Xu and Larbi, 2017). Molecules shed by 
pathogens or released by damaged tissues can recruit local macrophages, or other immune 
cells, to the immediate area and initiate an immune response (Xu and Larbi, 2017). These 
recruited immune cells will begin secreting early pro-inflammatory cytokines, such as tumor 
necrosis factor alpha (TNFα) and interferon gamma (INF-γ), that stimulate the production of 
vasodilators and draw additional immune cells to the area (Xu and Larbi, 2017). As the acute 
inflammatory response progresses, many of the secreted cytokines further polarize the 
gathering immune cells into an activated state (Mack, 2017). Once activated, these immune 
cells will secrete additional inflammatory cytokines, like interleukins 1 and 6 (IL-1 and IL-6) 
(Mack, 2017).  
 As inflammatory cytokines accumulate in the area, they trigger cascading pathways 
that further exacerbate the inflammatory response. Inflammatory cytokine signaling induces 
an enzyme, cyclooxygenase 2 (COX-2), to convert arachidonic acid (AA) into the central 
prostaglandin precursor, prostaglandin H2 (PGH2) (Aoki and Narumiya, 2012). This 
precursor can then be converted into various forms of prostaglandins (potent vasodilators) 
including, PGD2, PGE2, PGF2, PGI2, and thromboxane-A2 (Aoki and Narumiya, 2012). 
 9 
PGE2 plays an important role in creating an inflammatory positive feedback loop by binding 
to a receptor that increases the production of the transcription-regulating protein NF-κB 
(Aoki et al., 2011). Once produced in appreciable quantities, NF-κB accumulates in the 
nucleus and induces the expression of pro-inflammatory genes, including COX-2 (Aoki et 
al., 2011). The succeeding production of COX-2 completes the loop by converting more AA 
into PGH2, and then PGH2 into PGE2 (Aoki et al., 2011). 
 The NF-κB pathway is a crucial part of the acute inflammatory response, as 
phosphorylated NF-κB proteins increase the expression of inflammatory genes in immune 
cells. Moreover, this pathway has been directly linked to the pathogenesis of several chronic 
inflammatory disorders, including cancer, when it remains in an upregulated and activated 
state (Aoki et al., 2011; Tilborghs et al., 2017). The NF-κB protein is generally thought of as 
heterodimer consisting of the p65 and p50 subunits, both of which remain bound to 
inhibitory IkB proteins before an inflammatory response (Tilborghs et al., 2017). However, 
pro-inflammatory molecules like microbial lipopolysaccharides (LPS), TNFα, and IL-1 can 
activate IkB kinases (IKK1 and IKK2), which subsequently degrade the inhibitory IkB 
proteins bound to the NF-κB subunits, ultimately leading to the activation of the NF-κB 
pathway (Tilborghs et al., 2017). 
 Inflammatory pathways, such as the NF-κB pathway, are prime targets for 
conventional drugs like glucocorticoids and nonsteroidal anti-inflammatory drugs (NSAIDs). 
Glucocorticoids are a common class of steroidal drugs administered for attenuating immune 
responses and decreasing inflammation (Press et al., 2016). They are able to easily pass 
through cell membranes due to their lipophilic nature, and once inside a cell they readily bind 
to glucocorticoid receptors in multiple signaling pathways (Press et al., 2016). Once bound to 
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their receptors, glucocorticoids exhibit pleiotropic anti-inflammatory effects, which have 
been shown to alleviate inflammation through genomic and non-genomic mechanisms (Press 
et al., 2016). On the genomic level, receptor-bound glucocorticoids are known to translocate 
into a cell’s nucleus, promote transcription of anti-inflammatory genes, and subsequently 
increase the production of anti-inflammatory cytokines (e.g. IL-4, IL-10, and IL-13) (Press et 
al., 2016). Outside of the nucleus, glucocorticoids can bind to membrane receptors, many of 
which are linked to rapid signaling systems, and therefore release cytosolic proteins to quell 
inflammatory signaling (Press et al., 2016). 
 Steroidal drugs are highly effective at treating inflammatory conditions, but even 
short term use can induce unwanted side effects such as high blood pressure, osteoporosis, 
cataracts, insulin resistance, and increased susceptibility to infections. Thus, it is far more 
common for primary health care providers to recommend NSAIDs (e.g. aspirin, ibuprofen, 
naproxen, etc.), many of which are readily accessible without a prescription (Dwivedi et al., 
2015). As their name implies, NSAIDs are not steroids, but they share therapeutic 
mechanisms with steroids like blocking the synthesis of prostaglandins (Dwivedi et al., 
2015). Most NSAIDs inhibit COX-1 and COX-2 enzymes, which limits the amount of AA 
available to be converted into various prostaglandins (Dwivedi et al., 2015). While NSAIDs 
represent favorable temporary treatments for inflammation, prolonged use may also result in 
medical complications (Dwivedi et al., 2015). Many NSAIDs are non-selective in their 
inhibitory-binding to COX like proteins, which can result in adverse complications for the 
cardiovascular system, the kidneys, the liver, and the gastrointestinal (GI) tract (Dwivedi et 
al., 2015). For example, COX-1 is important for maintaining the protective GI mucosa, but 
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prolonged NSAID consumption can wear away the GI mucosa and leave the GI tract 
susceptible to infection (Dwivedi et al., 2015; Gudis and Sakamoto, 2005). 
 Overall, both steroidal drugs and NSAIDs are generally regarded as safe when taken 
as prescribed by physicians, but they are not always accessible by rural communities. 
Nevertheless, the prevalence of natural products can provide comparable treatment options 
for inflammatory disorders (Abdull Razis et al., 2014). In fact, many of these natural 
products contain potent bioactive compounds that are pharmacologically similar to 
conventional anti-inflammatory drugs (Gautam and Jachak, 2009). Several studies have 
found that bioactive compounds isolated from M. oleifera extracts act on a variety of 
inflammatory pathways including the AA pathway, the inducible nitric oxide synthase 
(iNOS) pathway, and the NF-κB pathway (Gautam and Jachak, 2009). A prominent bioactive 
compound that is frequently isolated from M. oleifera leaf extracts is kaempferol, which 
inhibits inflammatory signaling in the NF-κB pathway and limits the production of several 
inflammatory cytokines like IL-1, IL-6, and TNFα (Rajendran et al., 2014). Of course, there 
are many other anti-inflammatory compounds in M. oleifera that can attenuate inflammatory 
processes by preventing the secretion of inflammatory cytokines, deactivating COX enzymes 
that produce prostaglandins, or inhibiting the expression of inflammatory response genes 
(Gautam and Jachak, 2009). 
 
1.3 Extraction and Identification of Bioactive Compounds in Moringa oleifera 
 Although it is not uncommon for natural products to be consumed raw or minimally 
processed, herbalists and nutraceutical researchers alike often develop extracts from natural 
products to concentrate their bioactive compounds (Sultana et al., 2009). These extractions 
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often use a variety of solvents including water, methanol, ethanol, acetone, ethyl acetate, as 
well as many other organic solvents (Sultana et al., 2009). Numerous researchers, using a 
variety of solvents, have shown that hydro-organic solvents (generally in concentrations 
ranging from 50% to 70% organic solvent) appear to be the most effective at recovering 
phenolic and flavonoid compounds; since these are the major classifications of bioactive 
compounds found in the M. oleifera plant, many M. oleifera products are extracted with 
aqueous organic solvent mixtures (Sultana et al., 2009; Vongsak et al., 2013). These aqueous 
organic mixtures typically increase the solubility of bioactive compounds within the chosen 
solvent, which ultimately results in larger extraction yields of phenolic compounds 
(Rodríguez-Pérez et al., 2015).  
 After choosing an appropriate solvent, there are a number of extraction techniques 
utilized to isolate bioactive compounds from natural product plant matrices such as 
“squeezing”, maceration, decoction, percolation, Soxhlet extraction, and ultrasound-assisted 
extraction (Rodríguez-Pérez et al., 2015; Vongsak et al., 2013). Squeezing is a rudimentary 
extraction technique where plant material is first dampened with a desired solvent, and then 
the wet mixture is pressed or squeezed through a filter before collection (Vongsak et al., 
2013). Maceration (commonly referred to as solid-liquid extraction) and decoction are very 
similar techniques that involve fully soaking the finely ground plant material in a solvent for 
a short amount of time (usually less than an hour or two); the main difference between these 
two techniques is that the solvent for decoction is usually kept heated or close to boiling 
(Rodríguez-Pérez et al., 2015; Vongsak et al., 2013). Percolation and Soxhlet extraction are 
techniques that involve heating the solvent, similar to decoction, but the boiling solvent does 
not remain in constant contact with the plant material (Vongsak et al., 2013). In these 
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extractions the solvent is heated until boiling, and then rising vapor condense back down 
onto the plant material before being filtered back into the heating flask (Vongsak et al., 
2013). Finally, several of the aforementioned techniques can be enhanced using machines to 
increase agitation during the extraction process such as placing the apparatus on a shaker, or 
using a sonicator to disrupt the mixture with ultrasonic waves (Rodríguez-Pérez et al., 2015; 
Sultana et al., 2009).    
 Overall, choosing an appropriate solvent and efficient technique is an important first 
step in the extraction process, but the reaction conditions under which the extraction takes 
place are also important to consider. The extraction temperature has a pronounced positive 
effect on extraction yield, yet it can negatively affect the bioactivity of the extracted 
compounds (Sultana et al., 2009). When researchers quantified the extraction yields (grams 
of final product divided by grams of initial plant material) of several natural products, 
including a M. oleifera extract, they saw a significant increase in yield when the plant 
material was extracted under reflux conditions (Sultana et al., 2009). Yet, when they 
analyzed the total phenolic and flavonoid content of these extracts, they saw significant 
decreases in both classifications of bioactive compounds (Sultana et al., 2009). They 
therefore concluded that increasing the reaction temperature of an extraction likely decreases 
its potency, because it degrades the thermolabile bioactive compounds, like phenols and 
flavonoids (Sultana et al., 2009). 
 Following the extraction process, the resulting mixture of solvent and plant chemicals 
is referred to as a whole extract, and there is a substantial amount of scientific reports that 
detail the therapeutic effects associated with M. oleifera whole seed and leaf extracts. 
However, the focus of the scientific community has largely been shifting away from whole 
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extract studies in favor of analytical studies that seek to isolate and identify extracted 
compounds. Subsequently, more researchers are using analytical chemistry techniques to 
characterize the bioactive compounds in their extracts (Rodríguez-Pérez et al., 2015). High-
performance liquid chromatography (HPLC), which is often paired with mass spectrometry, 
is probably the most common analytical technique for separating and identifying compounds 
in complex extraction samples (Rodríguez-Pérez et al., 2015). Nevertheless, there are many 
other separation and identification techniques in use, such as gas chromatography (GC), thin 
layer chromatography (TLC), counter current chromatography (CCC), and nuclear magnetic 
resonance (NMR) spectroscopy to name a few (Yang et al., 2016; Sreelatha et al., 2011). 
 HPLC instruments have been a staple in industrial research laboratories since the 
1980s, and HPLC separation techniques are frequently used in pharmaceutical research 
facilities due to their high-resolution capabilities and relatively fast run times (Wirtz, 2014). 
Other advantages to using HPLC separation include low run temperatures (which decreases 
thermolabile sample degradation), reduced solvent waste, variable solid-phases, and the 
ability to couple the instrument with a multitude of detectors (like time-of-flight mass 
spectrometers) for analyte identification (Wirtz, 2014). As the name suggests, HPLC 
separates compounds in a liquid mixture using column chromatography. This means that a 
liquid sample is injected into the HPLC system (usually < 100 microliters), where it will mix 
with the mobile-phase solvent(s) that transports the sample to the column (Wirtz, 2014). 
Common solvents used for HPLC mobile-phases include tetrahydrofuran (THF), 
trifluoroacetic acid (TFA), formic acid, acetic acid, ammonium acetate, acetonitrile, and 
methanol (Wirtz, 2014).  
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 After mixing with the mobile-phase, the sample will travel to the HPLC column 
where it undergoes separation by interacting with the stationary-phase (Wirtz, 2014). The 
inside of the column (or stationary phase) is packed with tiny silica-gel particles (particles    
< 2 micrometers in diameter), which are engineered to have varying degrees of separation 
selectivity (Wirtz, 2014). The selectivity of the column packing material is dependent on 
optimal run conditions though, so pH and temperature ranges must be taken into account 
when choosing a suitable stationary-phase (Wirtz, 2014). As the sample runs through the 
column, analytes with a higher affinity for the packing material will stay in the column 
longer, while analytes with a lower affinity will quickly move through the column and into 
the detector, effectively separating sample matrix. 
 Finally, once the analytes have been separated by their run through the HPLC 
column, they are transported to a detector which will generate a chromatograph and help 
identify chemical compounds in the sample. Mass spectrometer (MS) coupled detectors are 
commonly implemented in natural product research, and can characterize ionized analytes 
based on their mass-to-charge ratio (m/z) (Wirtz, 2014). Inside the MS, ionized analytes are 
ejected into a high vacuum environment (10–5 to 10–7 torr) where magnetic and electrical 
fields separate the ions based on their masses (Wirtz, 2014). Of course, there are several 
different types of mass analyzers that can quantify an ionized analyte’s mass-to-charge ratio, 
but time-of-flight (TOF) mass analyzers have become exceedingly commonplace in the 
biomedical sciences (Wirtz, 2014). In TOF MS, ionized analytes are accelerated with an 
electrical field through a drift tube, where lighter ions will travel faster than heavier ions; 
thus, the ion’s mass-to-charge ratio can be determined by measuring the time that it takes for 
an ion to travel from the ionization source to the detector (Wirtz, 2014). 
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 To truly understand the therapeutic potential of M. oleifera natural products, extracted 
bioactive compounds must be isolated, identified, and empirically tested to show their 
contribution in medicinal whole extracts. Current studies attribute M. oleifera’s numerous 
medicinal properties to the large yields of phytochemicals that can be extracted from the 
plant matter, especially secondary metabolites like alkaloids, tannins, flavonoids, quinones, 
phenols, and phenolic acids (Gupta et al., 2017; Brilhante et al., 2017).  While extracted 
chemical composition varies greatly depending on aforementioned factors (plant material, 
extraction solvent, extraction technique, etc.), commonly extracted bioactive compounds 
with known health benefits include caffeolyquinic acids, flavonoids (kaempferol and 
quercetin), glucosinolates, and glycosides (Brilhante et al., 2017). These groupings of 
bioactive compounds have exhibited salutary effects when tested for antimicrobial, 
anticancer, and anti-inflammatory/ immunomodulatory capabilities (Gupta et al., 2017; 
Brilhante et al., 2017). 
 As mentioned earlier, overuse of antibiotics has led to the rise of drug-resistant 
microbial strains, so researchers are trying to isolate bioactive compounds that may be used 
to generate new antimicrobial agents (Brilhante et al., 2017). Some antimicrobial compounds 
isolated from M. oleifera extracts include gallic acid, sapponins, phenolic alkaloids, thymol, 
tannins, glucomoringin, glucosinolates, and kaempferol derivatives (Gupta et al., 2017; 
Brilhante et al., 2017). Certain antimicrobial compounds, like benzyl isothiocyanate, have 
been shown to suppress bacterial growth (by disrupting bacterial membranes) with results 
comparable to standard antibiotics (Brilhante et al., 2017). M. oleifera extracts also appear to 
have antiviral chemicals, like isocyanates and niaziminin, which were able to inhibit viral 
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replication in several strains of herpesvirus in vitro (Gupta et al., 2017; Brilhante et al., 
2017). 
 Researchers are also looking at M. oleifera extracts for their anticancer effects. Some 
extracts contain antitumor and anti-proliferative compounds, which are being proposed for 
use in new combinatorial cancer therapies. Interestingly, two of the previously mentioned 
antimicrobial compounds, niaziminin and benzyl isothiocyanate, have been shown to have 
tumorcidal capabilities in vitro (Brilhante et al., 2017). Other isolated compounds that have 
shown in vitro antitumor potential include 3-O-(6’-O-oleoyl-β-D-glucopyranosyl)-β-
sitosterol, β-sitosterol-3-O-β-D-glucopyranoside, kaempferol, quercetin, and derivatives of 
both  phenylacetonitrile and quinic acid (Gupta et al., 2017; Brilhante et al., 2017). It is 
important to note that many of these bioactive compounds have the desirable property of 
exhibiting cytotoxic effects in several cancerous cell lines, but do not appear to harm healthy 
cells (Brilhante et al., 2017). 
 Finally, analytical scientists are elucidating the chemicals that give M. oleifera 
extracts their potent anti-inflammatory and immunomodulatory capabilities. Numerous 
publications have reported on the in vitro and in vivo immunomodulatory effects of whole 
extracts, and several of these studies have compared M. oleifera extracts to common NSAIDs 
(Brilhante et al., 2017).  Impressively, these plant extracts exhibited similar or better anti-
inflammatory effects compared to non-prescription anti-inflammatory drugs (Brilhante et al., 
2017). These anti-inflammatory effects are attributed to extracted compounds inhibiting 
inflammatory signaling from immune cells and also decreasing inflammatory gene 
expression (Gupta et al., 2017; Brilhante et al., 2017). For example, quercetin and 
kaempferol have been shown to inhibit the activation of the NF-κB pathway, decrease the 
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release of inflammatory cytokines (IL-6 and TNFα), and regulate the expression of some 
proteins (like iNOS, IFN-γ, and C-reactive protein) (Rajendran et al., 2014; Brilhante et al., 
2017). Other extracted anti-inflammatory compounds believed to work through similar 
mechanisms include linoleic acid, oleanolic acid, thymol, thymoquinone, and resveratrol 
(Gautam and Jachak, 2009; Brilhante et al., 2017).  
 
1.4 Current Project Overview 
 Previous studies have shown potent anti-inflammatory and anticancer effects 
associated with ethanolic Moringa oleifera whole-leaf extracts. To further investigate the 
therapeutic properties and potential applications of these ethanolic extracts, this current 
project used high performance liquid chromatography (HPLC) to separate bioactive 
compounds from the whole ethanolic extract into distinct subfractions. We hypothesized that 
these HPLC-isolated M. oleifera subfractions might exhibit therapeutic effects in a cancer 
microenvironment by decreasing cancer cell viability and attenuating inflammatory cytokine 
production. In order to test this hypothesis, our project had three main goals including 1) 
isolating bioactive compounds from the whole ethanolic extract into discrete subfractions 
using HPLC separation techniques, 2) evaluating the anti-inflammatory and 
immunomodulatory properties of these subfractions, and 3) assessing the ability of these 
subfractions to decrease cervical cancer cell viability and exploring the mechanisms 
contributing to any anticancer effects. From our assessments, we hope to explore therapeutic 
applications for these concentrated subfractions in various cancers and inflammatory 
diseases, as well as characterize each subfraction’s bioactive chemical profile. 
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Chapter Two 
2. Materials and Methods 
2.1 Cell Culture 
 THP-1 cells, a human monocytic leukemia cell line, were cultured at 37°C and 5% 
CO2 in enriched RPMI-1640 media. This RMPI media was further supplemented with 0.3 
g/L L-glutamine and sodium bicarbonate, 10% fetal bovine serum (FBS), 1% 
penicillin/streptomycin, 1% vitamins, 10 mM HEPES, and 0.05 mM 2-mercaptoethanol. 
HeLa and SiHa cervical cancer cells were also cultured at 37°C and 5% CO2 in DMEM 
media supplemented with 10% FBS. HeLa cells were the first immortalized cell line to be 
grown in culture, and they were acquired in 1952 from a 31 year old African American 
female (Rahbari et al., 2009). HeLa cells have recently been characterized as a rare 
adenocarcinoma (formed in epithelial glandular structures) and been shown to contain human 
papillomavirus (HPV)-18 DNA (Rahbari et al., 2009). SiHa cervical cancer cells are 
classified as a squamous cell carcinoma that have been shown to contain HPV-16 DNA; 
these cells were originally isolated from a 55 year old Asian female (Meissner, 1999). All 
cell lines were acquired from the American Type Culture Collection (ATCC). 
 
2.2 Whole Ethanolic Moringa Oleifera Extract 
 Previous studies in our labs have shown potential anti-inflammatory and anticancer 
effects associated with whole ethanolic extracts from Moringa oleifera leaves (Brown et al., 
2015). Therefore, we used the following extraction method to obtain our whole extract that 
was subsequently separated and analyzed with high performance liquid chromatography 
(HPLC). Dried M. oleifera leaf powder was obtained by Drs. Jahangir Emrani and Joshua 
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Idassi (North Carolina Agricultural and Technological State University). The dried leaf 
powder was extracted using maceration techniques with 200 proof ethanol as the solvent; 
each batch of leaf powder was extracted twice, both times with ethanol as the solvent, and the 
extraction mixtures were compiled together before filtration and concentration. Each batch of 
extraction mixture was filtered through double layered cheese-cloth, and then concentrated 
using rotary evaporation. Then, the concentrated whole ethanolic M. oleifera extract was 
either injected into the HPLC system, or it was further concentrated and reconstituted in 
deionized water to a final concentration of about 1 gram of original leaf powder (d.m.) per 1 
milliliter of water. These whole extracts were stored at –20°C until use. 
 
2.3 HPLC Generated Subfractions from Whole Ethanolic Moringa oleifera Extract 
 As mentioned in the previous section, part of the whole ethanolic M. oleifera extract 
would be concentrated and injected into an HPLC system for separation. The HPLC system 
that was used was a Varian-ProStar Model HPLC, equipped with a ProStar 410 AutoSampler 
and injection unit, two 210/215/218 SD-1 Pumps for solvent delivery, a ThermoFisher 
Hypersil GOLD C18 Selectivity Liquid Chromatography Column (Model Number 25012-
159070), and a ProStar 325 LC Detector that used a single channel for detecting ultraviolet 
(UV) radiation at 330 nanometers. For each separation run, 100 microliters of concentrated 
whole ethanolic M. oleifera extract would be injected into the HPLC system and separated 
over a run time of 55 minutes. During a 55 minute run, the solvent being pumped through the 
system gradually changed from a solution of 0.1% formic acid in water to a solution of 0.1% 
formic acid in acetonitrile. The separated effluent mixture was collected in several intervals 
to generate 8 total subfractions: subfraction 1 (0-6 minutes), subfraction 2 (6-11 minutes), 
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subfraction 3 (11-17 minutes), subfraction 4 (17-25 minutes), subfraction 5 (25-34 minutes), 
subfraction 6 (34-42 minutes), subfraction 7 (42-48 minutes), and subfraction 8 (48-55 
minutes). These subfractions were compiled over several runs and subsequently concentrated 
and reconstituted in deionized water. While most of the subfractions were thoroughly tested 
for immunomodulatory and anticancer properties, subfraction 1 was not able to be 
concentrated to useable levels and was regarded as HPLC forerun (mostly containing 
acidified water).  The concentrated and reconstituted subfractions were stored at –20°C until 
needed. 
 
2.4 Collection of THP-1 Cell Supernatants for Anti-inflammatory Assays 
 THP-1 monocytes were pretreated with M. oleifera whole extract and subfractions, 
and then challenged with lipopolysaccharides (LPS) to determine if the extracted solutions 
had any immunomodulatory capabilities. First, THP-1 monocytes were collected and 
centrifuged at 1400 rpms for 4 minutes, and the supernatant was discarded. The centrifuged 
pellet was suspended in fresh RPMI media, and then 750,000 cells in fresh media were 
seeded into the wells of 12-well plates. Subsequently, each subfraction was added to an 
individual well until the final concentration ranged from 0-200 µg (d.m.)/mL. Alternatively, 
reconstituted whole ethanolic extract could be added to an individual well until the final 
concentration ranged from 0-200,000 µg (d.m.)/mL. The THP-1 cells and M. oleifera 
solutions were incubated for 4 hours at 37°C with 5% CO2 before being challenged with 675 
ng/mL of LPS. Following LPS challenge, the supernatant of the wells were collected in 
microcentrifuge tubes at 24 hour and 48 hour time-points. The collected supernatant was then 
centrifuged and stored at –80°C until needed. 
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2.5 Inflammatory Cytokine Quantification using ELISAs 
 Inflammatory cytokine levels (IL-6 or TNFα) from supernatants obtained from M. 
oleifera treated THP-1 cells were measured using enzyme-linked immunosorbent assays 
(ELISAs) as detailed in the manufacturer’s (BD OptEIA) protocol. First, inflammatory 
cytokine capture antibody was coated onto high-affinity binding ELISA plates overnight at 
4°C. Excess antibody was washed off, then plates were blocked with blocking buffer for 1 
hour at room temperature, followed by additional washes to remove excess blocking buffer. 
Next, M. oleifera pretreated THP-1 supernatants were added to the wells and incubated for 2 
hours at room temperature. The plate was thoroughly washed, and detection antibody was 
incubated with the plate for 1 hour at room temperature. After a final series of washes, 
substrate solution was added to the ELISA plate at room temperature for 30 minutes in the 
dark. Finally, stop solution was added to each well, and the ELISA plate was immediately 
read using a spectrophotometer set to measure absorbance at 450 nm with a wave correction 
set to 570 nm. 
 
2.6 HeLa and SiHa Cervical Cancer Cell Viability Assays 
 HeLa or SiHa cells were treated with various concentrations of M. oleifera whole 
extract or subfractions for 24 or 48 hours. Cell viability was determined by a MTT cell 
viability assay according to the manufacturer’s (Roche Diagnostics) protocol. Cancer cells 
suspended in DMEM were seeded into 96-well plates and incubated at 37°C with 5% CO2 
until the wells were around 70% confluent. Upon reaching confluency, M. oleifera 
subfractions or whole ethanolic extract was added until the final concentration ranged from 
0-200 µg (d.m.)/mL (or 0-200,000 µg (d.m.)/mL for the whole ethanolic extract). These 
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plates were placed back in the incubator for 24 or 48 hours, and then each well received MTT 
labeling reagent. After 4 hours of incubation with the MTT reagent, a solubilizing reagent 
was added to each well and further incubated overnight at 37°C. Finally, the plate was read 
with a spectrophotometer set to measure absorbance at 570 nm.  
 Additionally, the cervical cancer cell viability was assessed after the application of 
combinations of M. oleifera subfractions. The following subfraction combinations were 
applied to HeLa or SiHa cancer cells at 70% confluency to determine their impact on cell 
viability: subfractions 2&3; 2&5; 2&7; 2&8; 3&5; 3&7; 3&8; 5&7; 5&8; 7&8; 2, 3&5; 2, 
5&7; 3, 5&7; 3, 5&8.  The subfraction combination MTT assay followed a similar procedure 
as described above. 
 
2.7 Collection of HeLa Cell Lysates for Western Blot Analysis 
 HeLa cervical cancer cells were treated with M. oleifera whole extract and 
subfractions to determine their anticancer properties. HeLa cells were suspended in DMEM 
and seeded into 6-well plates; these plates were incubated at 37°C with 5% CO2 until the 
wells were around 70% confluent. Upon reaching confluency, M. oleifera subfractions or 
whole ethanolic extract was added until the final concentration ranged from 0-100 µg 
(d.m.)/mL. These plates were placed back into the incubator for 24 hours. The supernatant 
was subsequently removed and RIPA lysate solution (containing aprotinin) was added to 
each well for 3 minutes while being kept cool on ice. The resulting lysates were then sheared 
using a 20 gauge syringe, and the protein concentration of each lysate was determined using 
a Pierce BCA Protein Assay Kit following the manufacturer’s (Thermo Scientific) protocol. 
The remaining lysates were quickly transferred and stored at –80°C until needed. 
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2.8 Western Blot Analysis of Anticancer Pathways 
 The lysates mentioned previously were used in Western blot analysis to determine if 
the M. oleifera solutions would alter any of the common inflammatory or proliferative 
pathways in cancer cells. Approximately 15 µg of protein from each subfraction or whole 
extract lysate were loaded into a precast polyacrylamide gel and separated using 
electrophoresis. The separated proteins were then transferred to a nitrocellulose membrane. 
Immunoblots were generated with antibodies against phosphorylated and total NF-κB, as 
well as Bax and Bcl-xL, with β-actin being the internal standard (all from Cell Signaling 
Technology). These blots were subsequently incubated with horseradish peroxidase (HRP) 
linked secondary antibodies, and then Dura (Thermo Scientific) luminol was used to 
visualize the signal in combination with a gel imager. Finally, ImageQuant TL v2005 was 
used to quantify relative band intensities. 
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Chapter Three 
3. Results 
3.1 HPLC Chromatograph and Generation of Subfraction Groups 
 Previous results on the anti-inflammatory and anticancer effects of various Moringa 
oleifera whole leaf extracts led us to further investigate the therapeutic potential of the 
ethanolic M. oleifera leaf extract (Brown et al., 2015). Following the previously established 
protocol, an ethanolic M. oleifera leaf extract was generated, concentrated using rotary 
evaporation, and subsequently separated through our high performance liquid 
chromatography (HPLC) system (Brown et al., 2015). A detector set to the 330 nm 
wavelength channel was used to generate a HPLC chromatograph, and the effluent sample-
solvent mixture from the 55 minute HPLC run was collected in test tubes during 1 minute 
cycles. Using the newly generated chromatograph (Figure 1), the 55 test tubes of effluent 
solution were combined into 8 distinct subfraction groupings. The test tubes were combined 
to generate the following subfraction groups: subfraction 1 (0-6 minutes), subfraction 2      
(6-11 minutes), subfraction 3 (11-17 minutes), subfraction 4 (17-25 minutes), subfraction 5 
(25-34 minutes), subfraction 6 (34-42 minutes), subfraction 7 (42-48 minutes), and 
subfraction 8 (48-55 minutes). 
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 After generating the HPLC chromatograph (Figure 1), it was observed that there were 
two main time frames in which detectable analytes were eluting through the column. The 
first region was early in the run, when the primary solvent moving through the column was 
acidified water, which occurred between 7 and 17 minutes. The second region of detectable 
analytes occurred much later in the run, when the primary solvent had switched over to 
acidified acetonitrile, which occurred between 34 and 48 minutes. While 8 total subfraction 
groupings were generated using natural breaks in the chromatograph, it is worth noting that 
subfraction 1 was left out of subsequent analysis after being deemed as forerun (mostly 
aqueous solvent with no appreciable amounts of analytes) from the HPLC system. 
 
3.2 Immunomodulatory Effects of M. oleifera Ethanolic Subfractions 
 Several studies have shown the anti-inflammatory potential of M. oleifera extracts, 
including ethanolic M. oleifera leaf extracts, which have been shown to alter inflammatory 
cytokine secretion (IL-1, IL-6, TNFα, etc.) from lipopolysaccharide (LPS)-stimulated 
macrophages (Fard et al., 2015). Since the subfractions we generated were isolated from an 
ethanolic M. oleifera leaf extract, we hypothesized that some of these subfractions should 
Figure 1. HPLC Chromatograph and Subfraction Groupings. Ethanolic M. oleifera 
leaf extract was separated using HPLC techniques and the chromatograph above was 
generated over a 55 minute run with a UV-Vis detector set at 330 nm. A total of 8 
subfraction groupings were established based on observed gaps in analyte peaks. 
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also exhibit therapeutic anti-inflammatory effects. To determine the immunomodulatory 
properties of our subfractions, we used a similar LPS challenge model with THP-1 
monocytes, which were generously supplied to us from Dr. Darren Seals at Appalachian 
State University. THP-1 cells are frequently used as a model system for human monocytes as 
they mimic the inflammatory behavior of peripheral blood derived mononuclear cells after 
stimulation with LPS (Vasanth et al., 2015). We suspected that pretreatment with our HPLC-
isolated subfractions would decrease IL-6 and TNFα inflammatory cytokine secretion from 
THP-1 cells following LPS challenge  
 Approximately 750,000 THP-1 cells were seeded into the wells of a 12-well plate and 
were then pretreated with one of the HPLC generated subfractions (2-8) at concentrations of 
either 100 or 200 µg/mL. Additionally, the ethanolic M. oleifera whole leaf extract (W), from 
which the subfractions were derived, was applied at 100,000 and 200,000 µg/mL. The THP-1 
cells were incubated with the extracts for 4 hours before being challenged with 675 ng/mL of 
LPS, which stimulates potent immune responses and activates monocytes into inflammatory 
macrophages. The cells were then incubated for 24 hours, and supernatants were collected 
for enzyme-linked immunosorbent assays (ELISAs) to determine the effect of M. oleifera 
ethanolic subfractions on LPS-induced secretion of inflammatory cytokines, interleukin-6 
(IL-6) and tumor necrosis factor alpha (TNFα). ELISAs were performed according to the 
manufacturer’s protocol, and relative amounts of inflammatory cytokine production were 
compared to the LPS-only positive control sample as seen in Figures 2A and 2B. 
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Figure 2. Decrease in Inflammatory Cytokine Production from LPS-Stimulated THP-1 
Cells Pretreated with M. oleifera Subfractions. THP-1 monocytes were pretreated with 
ethanolic M. oleifera leaf extract (W) or a subfraction (2-8) for 4 hours. The cells were 
subsequently challenged with 750 ng/mL of LPS, and supernatants were collected after 24 
hours. A standard ELISA protocol was used to determine the amount of A) IL-6 or B) TNFα 
produced, and all values were normalized as a percentage of the LPS-only positive control. 
The concentrations for each extract are recorded in micrograms of original leaf powder per 
milliliter [µg/mL]. The data shown are an average of three experiments ± standard error. 
Asterisks indicate a significant reduction as compared to the LPS positive control (P = <0.05) 
using one-tailed Student’s t-tests. 
A 
 
B 
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 Data from the IL-6 ELISA (Figure 2A) showed that subfractions 4, 5, 6, 7, and 8 were 
all able to significantly reduce LPS-stimulated production of IL-6 when applied 4 hours 
before LPS challenge at a concentration of 200 µg/mL. Interestingly, the ethanolic M. 
oleifera whole leaf extract (W) was not able to significantly alter IL-6 production at 100,000 
µg/mL (a 1,000-fold higher concentration than any of the subfractions), but it did decrease 
IL-6 production similar levels of the mock negative control (DI water added instead of LPS) 
when applied at 200,000 µg/mL. Subfraction data from the TNFα ELISA (Figure 2B) 
showed similar reductions in cytokine production. However, all subfractions (2-8) were able 
to significantly reduce TNFα production when THP-1 cells were pretreated at a concentration 
of 200 µg/mL. Subfractions 3, 5, 7, and 8 also reduced TNFα production at the lower 
concentration of 100 µg/mL. Unlike the IL-6 data, the whole extract was able to significantly 
reduce TNFα production at both the 100,000 µg/mL and 200,000 µg/mL concentrations, with 
both treatments reducing TNFα cytokine production to levels comparable to the negative 
control. 
 
3.3 Anticancer Effects of Subfractions 
 Previous studies have shown that M. oleifera extracts have anti-proliferative and 
apoptotic effects on some cancer cell lines both in vitro and in vitro, and recent research has 
shown that modulating apoptotic pathways has promising therapeutic applications for a 
variety of cancers (Sreelatha et al., 2011). Building upon this information, previous studies in 
our labs have looked at the anti-proliferative and apoptotic potential of M. oleifera whole 
extracts in several cervical cancer cell lines, and data from these studies has shown that 
ethanolic whole leaf extracts are able to alter cervical cancer cell proliferation and induce 
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apoptosis (Brown et al., 2015). Thus, it was hypothesized that subfractions derived from 
ethanolic M. oleifera leaf extract may also induce anticancer effects in a HeLa and SiHa 
cervical cancer cell lines.  
 To test this hypothesis, HeLa (Figures 3A and 3B) and SiHa (Figures 4A and 4B) 
cervical cancer cells were seeded into the wells of 96-well plates at or near confluence         
(≈ 70% of surface area covered), allowed to adhere for approximately 4 hours, and then 
treated with either an individual subfraction or the ethanolic whole extract. Similar volumes 
of deionized water were added to wells to serve as negative controls (mock-treatment group). 
The cells were left to incubate with the extracts for 24 hours (Figures 3A and 4A) or 48 hours 
(Figures 3B and 4B), after which the cancer cell viability was determined using a MTT assay 
and reported as a percent of the negative control. 
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Figure 3. Changes in Viability of HeLa Cervical Cancer Cells after Treatment with 
M. oleifera Whole Extract and Subfractions. HeLa cervical cancer cells were treated 
with ethanolic M. oleifera leaf extract (W) or an individual subfraction (2-8) for 24 or 48 
hours. A MTT assay was used determine the cell viability after 24 hours of treatment (3A) 
or 48 hours after treatment (3B). The data were then normalized as a percentage of the 
mock-treated negative control, which received water in place of extract. The 
concentrations for each extract are recorded in micrograms of original leaf powder per 
milliliter [µg/mL]. The data shown are an average of three to five experiments ± standard 
error. Asterisks indicate a significant change in cell viability as compared to the mock-
treated negative control (P = <0.05) using one-tailed Student’s t-tests. 
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Figure 4. Changes in Viability of SiHa Cervical Cancer Cells after Treatment with 
M. oleifera Whole Extract and Subfractions. SiHa cervical cancer cells were treated 
with ethanolic M. oleifera leaf extract (W) or an individual subfraction (2-8) for 24 or 48 
hours. A MTT assay was used determine the cell viability after 24 hours of treatment (4A) 
or 48 hours after treatment (4B). The data were then normalized as a percentage of the 
mock-treated negative control, which received water in place of extract. The 
concentrations for each extract are recorded in micrograms of original leaf powder per 
milliliter [µg/mL]. The data shown are an average of three to five experiments ± standard 
error. Asterisks indicate a significant change in cell viability as compared to the mock-
treated negative control (P = <0.05) using one-tailed Student’s t-tests. 
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The MTT data corroborated previous results from our lab, showing that ethanolic 
whole extract (W) was able to significantly decrease cervical cancer cell viability at high 
treatment concentrations of 100,000 and 200,000 µg/mL; there was a notable exception to 
this reduction in cell viability in the SiHa cells measured after 24 hours, in which case both 
the 100,000 and 200,000 µg/mL treatment concentrations caused a significant increase in 
SiHa cell viability. While the whole extract exhibited promising anticancer effects at high 
concentrations, there were no decreases in HeLa or SiHa cancer cell viability when cells 
were treated with the whole extract at lower concentrations of 100 or 200 µg/mL. In fact, 
treatment with 200 µg/mL of ethanolic whole extract caused a significant increase in SiHa 
cell viability at both the 24 hour and 48 hour time point. 
In contrast to results obtained from the whole extract, individual subfractions at the 
lower concentrations did influence the viability of both HeLa and SiHa cells. Overall, the 
MTT data showed that HeLa cell viability decreased more significantly than SiHa cell 
viability when individual subfractions were added. HeLa cell viability generally decreased 
from treatment with 100 µg/mL to 200 µg/mL of subfractions, and there were also less viable 
cells after 48 hours compared to data from 24 hours. The subfractions that significantly 
decreased HeLa cell viability include subfractions 2, 3, 4, 5, 7, and 8, with subfraction 5 
causing the greatest decrease in cell viability.  
 As mentioned above, SiHa cancer cells responded much differently to treatment with 
individual subfractions as compared to HeLa cells. At the 24 hour time point, subfractions 3, 
5 and 8 significantly reduced SiHa cell viability (Figure 4A), but viability did not continue to 
decrease over time (Figure 4B). In fact, none of the individual subfractions caused a 
significant decrease in SiHa cell viability after 48 hours. Rather, treatment with subfractions 
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2, 3, 4, and 6 actually significantly increased cell viability by 48 hours. These data indicate 
that there are individual cancer cell differences that may influence the effects of M. oleifera 
subfractions on cellular viability, even when cells are derived from the same tissue.  
Seeing the therapeutic potential of several of the HPLC-isolated subfractions, we 
decided to test if combinations of these subfractions could further reduce HeLa and SiHa cell 
viability. Subsequently, we tested treatments with two and three subfraction combinations 
using the most promising subfractions (2, 3, 5, 7, and 8) according to data obtained in Figure 
3. Using a similar protocol for testing the individual subfractions, we generated a cancer cell 
viability heatmap to visually show the effects of subfraction combinations on HeLa (Figure 
5) and SiHa (Figure 6) cervical cancer cells. 
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24hr [100] 24hr [200] 48hr [100] 48hr [200]
W 102.0 104.8 96.7 101.6
2 96.4 96.0 92.8 90.2
3 86.0 98.7 89.4 92.3
4 98.4 96.0 95.8 88.2
5 83.0 73.4 76.5 67.3
6 96.0 97.3 101.5 101.5
7 96.9 97.0 93.3 87.3
8 93.3 90.1 95.9 94.4
2 & 3 96.8 91.2 91.5 79.8
2 & 5 89.4 76.0 74.3 59.2
2 & 7 93.8 88.8 78.3 71.3
2 & 8 88.2 88.0 80.1 76.3
3 & 5 92.4 88.3 75.7 65.6
3 & 7 94.3 92.7 79.1 77.3
3 & 8 93.4 92.7 77.9 75.5
5 & 7 94.0 85.2 78.5 63.2
5 & 8 97.4 87.8 83.9 66.7
7 & 8 96.7 92.8 81.7 80.6
2 & 3 & 5 92.3 83.3 79.3 57.5
2 & 5 & 7 91.9 83.2 69.6 53.9
3 & 5 & 7 91.4 87.5 72.3 58.0
3 & 5 & 8 92.8 85.1 75.1 62.9
55 - 65
45 - 55
105 -115
95 - 105
85 - 95
75 -85
65 - 75
Figure 5. Changes in HeLa Cervical Cancer Cell Viability after Treatment with 
Individual Subfractions and Combinations of subfractions. HeLa cervical cancer cells 
were treated with ethanolic M. oleifera leaf extract (W) or subfraction(s) (2-8) for 24 or 
48 hours, and a MTT assay was used determine the cell viability following treatment. The 
data were then normalized as a percentage of the mock-treated negative control. The 
darker blue samples indicate a greater decrease in cell viability relative to the mock-
control, while yellow indicates an increase in cell viability. The concentrations for each 
extract are recorded in micrograms of original leaf powder per milliliter [µg/mL]. The 
data shown are an average of three to six experiments. Bolded numbers indicate a 
significant change in cell viability (P = <0.05) using one-tailed Student’s t-tests. 
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As indicated in the results section of Figure 3, a temporal effect of individual 
subfractions becomes apparent when looking at HeLa cell viability in Figure 5, where there 
was a greater reduction in cell viability at the 48 hour time as compared to 24 hour time point 
Figure 6. Changes in SiHa Cervical Cancer Cell Viability after Treatment with 
Individual Subfractions and Combinations of subfractions. SiHa cervical cancer cells 
were treated with ethanolic M. oleifera leaf extract (W) or subfraction(s) (2-8) for 24 or 48 
hours, and a MTT assay was used determine the cell viability following treatment. The data 
were then normalized as a percentage of the mock-treated negative control. The darker blue 
samples indicate a greater decrease in cell viability relative to the mock-control, while yellow 
indicates an increase in cell viability. The concentrations for each extract are recorded in 
micrograms of original leaf powder per milliliter [µg/mL]. The data shown are an average of 
three to six experiments. Bolded numbers indicate a significant change in cell viability (P = 
<0.05) using one-tailed Student’s t-tests. 
24hr [100] 24hr [200] 48hr [100] 48hr [200]
W 103.7 109.5 99.7 107.7
2 96.7 95.3 101.7 102.8
3 84.1 98.2 89.5 111.2
4 101.9 100.6 106.6 106.3
5 92.7 82.9 94.1 88.0
6 100.7 102.2 105.8 113.5
7 99.9 98.1 104.2 105.3
8 93.2 91.5 95.9 93.3
2 & 3 98.3 88.7 90.0 80.2
2 & 5 82.4 60.1 75.8 51.9
2 & 7 97.5 93.7 91.6 82.0
2 & 8 97.2 93.8 90.1 84.4
3 & 5 75.9 54.8 77.0 53.8
3 & 7 96.7 90.6 89.6 80.6
3 & 8 96.1 91.0 89.8 80.0
5 & 7 79.0 58.2 83.0 58.7
5 & 8 78.2 56.1 82.1 55.0
7 & 8 91.5 84.4 92.2 81.2
2 & 3 & 5 77.8 51.1 80.1 50.2
2 & 5 & 7 78.2 56.1 76.7 50.5
3 & 5 & 7 80.7 56.2 79.1 52.1
3 & 5 & 8 79.4 54.0 79.6 51.7
55 - 65
45 - 55
105 -115
95 - 105
85 - 95
75 -85
65 - 75
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data. The visual data from Figure 5 also suggests that treatment with two or three subfraction 
combinations potentially decreases HeLa cell viability more than treatment with individual 
subfractions, especially when applied for 48 hours. 
The temporal effect seen in HeLa cells does not appear to apply when looking at SiHa 
cell viability in Figure 6. Rather, there is a more pronounced effect on the treatment 
concentration of subfraction combinations when looking at SiHa cell viability. Data from 
Figure 6 shows considerable decreases in SiHa cell viability when subfraction combinations 
were treated at a concentration of 200 µg/mL instead of 100 µg/mL. It is also worth noting 
that in contrast to results seen for individual subfractions, no treatment combinations caused 
an increase in SiHa cell viability. Somewhat surprisingly, treatment with three subfraction 
combinations does not appear to drastically reduce SiHa cell viability any more than 
treatment with two subfraction combinations. 
Overall, treatment with subfraction combinations appears to significantly reduce 
cervical cancer cell viability. However, the MTT data from the subfraction combinations 
presented in Figures 5 and 6 do not directly compare combination treatments to their 
individual subfraction constituents. Therefore, we further analyzed the previously generated 
cell viability data in order to determine if subfraction combination treatments further reduced 
cell viability than an individual subfraction that made up the combination treatment. HeLa 
cell viability treatment differences were analyzed for significance in Tables 1 and 2 below, 
while SiHa cell viability treatment differences were analyzed for significance in Tables 3   
and 4. 
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Cell Viability (%) 2 [100] 3 [100] 5 [100] 7 [100] 8 [100] 2 [200] 3 [200] 5 [200] 7 [200] 8 [200]
Cell Viability (%) 96.4 86.0 83.0 96.9 93.3 96.0 98.7 73.4 97.0 90.1
2 & 3 [100] 96.8 0.9301 0.0849
2 & 3 [200] 91.2 0.5377 0.3523
2 & 5 [100] 89.4 0.2277 0.2641
2 & 5 [200] 76.0 0.1418 0.8230
2 & 7 [100] 93.8 0.2695 0.2002
2 & 7 [200] 88.8 0.1650 0.1377
2 & 8 [100] 88.2 0.2208 0.4208
2 & 8 [200] 88.0 0.0955 0.6433
3 & 5 [100] 92.4 0.2711 0.0768
3 & 5 [200] 88.3 0.2212 0.1130
3 & 7 [100] 94.3 0.1347 0.3283
3 & 7 [200] 92.7 0.2345 0.4100
3 & 8 [100] 93.4 0.1694 0.9839
3 & 8 [200] 92.7 0.1855 0.5653
5 & 7 [100] 94.0 0.0236 0.4099
5 & 7 [200] 85.2 0.1349 0.1241
5 & 8 [100] 97.4 0.0313 0.4002
5 & 8 [200] 87.8 0.1610 0.7974
7 & 8 [100] 96.7 0.9462 0.3544
7 & 8 [200] 92.8 0.3817 0.5400
2 & 3 & 5 [100] 92.3 0.3962 0.3001 0.1011
2 & 3 & 5 [200] 83.3 0.1931 0.1346 0.2998
2 & 5 & 7 [100] 91.9 0.3430 0.1049 0.2980
2 & 5 & 7 [200] 83.2 0.2060 0.3181 0.1808
3 & 5 & 7 [100] 91.4 0.3920 0.1585 0.3177
3 & 5 & 7 [200] 87.5 0.2554 0.1756 0.3251
3 & 5 & 8 [100] 92.8 0.2489 0.0714 0.9060
3 & 5 & 8 [200] 85.1 0.2126 0.2758 0.6109
Table 1. Treatment with Subfractions Combinations Compared to Individual 
Subfraction Constituents applied to HeLa cells for 24 hours. HeLa cervical cancer 
cells were treated with combinations of subfractions (2-8) over 24 hours, and cancer cell 
viability (CV) was measured using an MTT Assay. The data were then normalized as a 
percentage of the mock negative control, which received water in place of extract. 
Statistical analyses were performed to determine which subfraction combinations were 
significantly different from their individual subfraction constituents. The concentrations 
for each extract are recorded in micrograms of original leaf powder per milliliter [µg/mL]. 
The data shown are an average of three to six experiments ± standard error. Bolded 
numbers indicate a significant difference in cell viability (P = <0.05) using two-tailed 
Student’s t-tests. P-values highlighted in blue show combinations exhibiting significant 
reductions compared to their individual constituents, while yellow indicates a significant 
increase.  
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Cell Viability (%) 2 [100] 3 [100] 5 [100] 7 [100] 8 [100] 2 [200] 3 [200] 5 [200] 7 [200] 8 [200]
Cell Viability (%) 92.8 89.4 76.5 93.3 95.9 90.2 92.3 67.3 87.3 94.4
2 & 3 [100] 91.5 0.7326 0.5697
2 & 3 [200] 79.8 0.0447 0.0744
2 & 5 [100] 74.3 0.0006 0.8222
2 & 5 [200] 59.2 0.0008 0.1826
2 & 7 [100] 78.3 0.0049 0.0116
2 & 7 [200] 71.3 0.0086 0.0156
2 & 8 [100] 80.1 0.0674 0.0356
2 & 8 [200] 76.3 0.0662 0.0322
3 & 5 [100] 75.7 0.0086 0.9328
3 & 5 [200] 65.6 0.0061 0.7664
3 & 7 [100] 79.1 0.0811 0.0383
3 & 7 [200] 77.3 0.0518 0.0789
3 & 8 [100] 77.9 0.0911 0.0223
3 & 8 [200] 75.5 0.0340 0.0064
5 & 7 [100] 78.5 0.8368 0.0132
5 & 7 [200] 63.2 0.4197 0.0014
5 & 8 [100] 83.9 0.4567 0.0084
5 & 8 [200] 66.7 0.9179 0.0012
7 & 8 [100] 81.7 0.0361 0.0072
7 & 8 [200] 80.6 0.1891 0.0220
2 & 3 & 5 [100] 79.3 0.0609 0.1281 0.7917
2 & 3 & 5 [200] 57.5 0.0004 0.0018 0.0967
2 & 5 & 7 [100] 69.6 0.0028 0.5058 0.0030
2 & 5 & 7 [200] 53.9 0.0001 0.0152 0.0000
3 & 5 & 7 [100] 72.3 0.0040 0.6689 0.0026
3 & 5 & 7 [200] 58.0 0.0030 0.0656 0.0001
3 & 5 & 8 [100] 75.1 0.0185 0.8880 0.0033
3 & 5 & 8 [200] 62.9 0.0038 0.3990 0.0004
Table 2. Treatment with Subfractions Combinations Compared to Individual 
Subfraction Constituents applied to HeLa cells for 48 hours. HeLa cervical cancer 
cells were treated with combinations of subfractions (2-8) over 48 hours, and cancer cell 
viability (CV) was measured using an MTT Assay. The data were then normalized as a 
percentage of the mock negative control, which received water in place of extract. 
Statistical analyses were performed to determine which subfraction combinations were 
significantly different from their individual subfraction constituents. The concentrations 
for each extract are recorded in micrograms of original leaf powder per milliliter [µg/mL]. 
The data shown are an average of three to six experiments ± standard error. Bolded 
numbers indicate a significant difference in cell viability (P = <0.05) using two-tailed 
Student’s t-tests. P-values highlighted in blue show combinations exhibiting significant 
reductions compared to their individual constituents, while yellow indicates a significant 
increase.  
 40 
 
 
 
 
 
 
 
 
 
 
 
  
 
Cell Viability (%) 2 [100] 3 [100] 5 [100] 7 [100] 8 [100] 2 [200] 3 [200] 5 [200] 7 [200] 8 [200]
Cell Viability (%) 96.7 84.1 92.7 99.9 93.2 95.3 98.2 82.9 98.1 91.5
2 & 3 [100] 98.3 0.7498 0.0403
2 & 3 [200] 88.7 0.2208 0.0871
2 & 5 [100] 82.4 0.0042 0.0144
2 & 5 [200] 60.1 0.0002 0.0041
2 & 7 [100] 97.5 0.8307 0.4689
2 & 7 [200] 93.7 0.6202 0.2860
2 & 8 [100] 97.2 0.8461 0.0863
2 & 8 [200] 93.8 0.7559 0.6557
3 & 5 [100] 75.9 0.1263 0.0001
3 & 5 [200] 54.8 0.0000 0.0004
3 & 7 [100] 96.7 0.0452 0.4290
3 & 7 [200] 90.6 0.1115 0.1731
3 & 8 [100] 96.1 0.0478 0.3688
3 & 8 [200] 91.0 0.1670 0.9265
5 & 7 [100] 79.0 0.0094 0.0010
5 & 7 [200] 58.2 0.0008 0.0000
5 & 8 [100] 78.2 0.0037 0.0028
5 & 8 [200] 56.1 0.0002 0.0000
7 & 8 [100] 91.5 0.0408 0.6209
7 & 8 [200] 84.4 0.0192 0.1489
2 & 3 & 5 [100] 77.8 0.0042 0.3007 0.0137
2 & 3 & 5 [200] 51.1 0.0000 0.0001 0.0005
2 & 5 & 7 [100] 78.2 0.0042 0.0147 0.0021
2 & 5 & 7 [200] 56.1 0.0011 0.0083 0.0006
3 & 5 & 7 [100] 80.7 0.5319 0.0181 0.0020
3 & 5 & 7 [200] 56.2 0.0006 0.0043 0.0002
3 & 5 & 8 [100] 79.4 0.4401 0.0310 0.0263
3 & 5 & 8 [200] 54.0 0.0001 0.0009 0.0001
Table 3. Treatment with Subfractions Combinations Compared to Individual 
Subfraction Constituents applied to SiHa cells for 24 hours. SiHa cervical cancer cells 
were treated with combinations of subfractions (2-8) over 24 hours, and cancer cell 
viability (CV) was measured using an MTT Assay. The data were then normalized as a 
percentage of the mock negative control, which received water in place of extract. 
Statistical analyses were performed to determine which subfraction combinations were 
significantly different from their individual subfraction constituents. The concentrations 
for each extract are recorded in micrograms of original leaf powder per milliliter [µg/mL]. 
The data shown are an average of three to six experiments ± standard error. Bolded 
numbers indicate a significant difference in cell viability (P = <0.05) using two-tailed 
Student’s t-tests. P-values highlighted in blue show combinations exhibiting significant 
reductions compared to their individual constituents, while yellow indicates a significant 
increase.  
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While data analysis from Tables 1 – 4 does show that many subfraction combination 
treatments did not perform significantly better than some of their individual subfraction 
constituents, numerous other combination treatments significantly outperformed their 
Cell Viability (%) 2 [100] 3 [100] 5 [100] 7 [100] 8 [100] 2 [200] 3 [200] 5 [200] 7 [200] 8 [200]
Cell Viability (%) 101.7 89.5 94.1 104.2 95.9 102.8 111.2 88.0 105.3 93.3
2 & 3 [100] 90.0 0.0035 0.9486
2 & 3 [200] 80.2 0.0000 0.0035
2 & 5 [100] 75.8 0.0005 0.0043
2 & 5 [200] 51.9 0.0000 0.0018
2 & 7 [100] 91.6 0.0129 0.0093
2 & 7 [200] 82.0 0.0000 0.0096
2 & 8 [100] 90.1 0.0041 0.2062
2 & 8 [200] 84.4 0.0009 0.1140
3 & 5 [100] 77.0 0.1623 0.0054
3 & 5 [200] 53.8 0.0006 0.0064
3 & 7 [100] 89.6 0.9934 0.0033
3 & 7 [200] 80.6 0.0016 0.0061
3 & 8 [100] 89.8 0.9712 0.1706
3 & 8 [200] 80.0 0.0038 0.0287
5 & 7 [100] 83.0 0.0203 0.0005
5 & 7 [200] 58.7 0.0075 0.0008
5 & 8 [100] 82.1 0.0145 0.0116
5 & 8 [200] 55.0 0.0032 0.0001
7 & 8 [100] 92.2 0.0112 0.3561
7 & 8 [200] 81.2 0.0075 0.0375
2 & 3 & 5 [100] 80.1 0.0001 0.2628 0.0098
2 & 3 & 5 [200] 50.2 0.0000 0.0002 0.0036
2 & 5 & 7 [100] 76.7 0.0000 0.0031 0.0001
2 & 5 & 7 [200] 50.5 0.0000 0.0032 0.0004
3 & 5 & 7 [100] 79.1 0.2247 0.0059 0.0002
3 & 5 & 7 [200] 52.1 0.0002 0.0036 0.0004
3 & 5 & 8 [100] 79.6 0.2425 0.0067 0.0054
3 & 5 & 8 [200] 51.7 0.0003 0.0044 0.0002
Table 4. Treatment with Subfractions Combinations Compared to Individual 
Subfraction Constituents applied to SiHa cells for 48 hours. SiHa cervical cancer cells 
were treated with combinations of subfractions (2-8) over 48 hours, and cancer cell 
viability (CV) was measured using an MTT Assay. The data were then normalized as a 
percentage of the mock negative control, which received water in place of extract. 
Statistical analyses were performed to determine which subfraction combinations were 
significantly different from their individual subfraction constituents. The concentrations 
for each extract are recorded in micrograms of original leaf powder per milliliter [µg/mL]. 
The data shown are an average of three to six experiments ± standard error. Bolded 
numbers indicate a significant difference in cell viability (P = <0.05) using two-tailed 
Student’s t-tests. P-values highlighted in blue show combinations exhibiting significant 
reductions compared to their individual constituents, while yellow indicates a significant 
increase.  
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individual constituent subfractions in reducing cervical cancer cell viability. Thus, Table 5 
below was constructed to summarize which subfraction combination treatments were 
significantly more effective at reducing cell viability than individual subfractions. 
  
 
 
  
 
 
 
  
Table 5A shows that the treatment combination of subfractions 5 & 7, as well as 
subfractions 5 & 8, actually increased HeLa cell viability compared to treating HeLa cells 
with subfraction 5 only (with a treatment concentration of 100 µg/mL after 24 hours). 
Similarly, the treatment combinations of 2 & 3, 3 & 7, and 3 & 8 increased SiHa cell 
A 
B 
Table 5. Subfraction Combinations that Significantly Changed Cancer Cell Viability 
Compared to Individual Constituents. The statistical analyses comparing treatment with 
subfraction combinations to individual constituents were summarized for HeLa (A) and SiHa 
(B) cervical cancer. Significant increases in cell viability from combination treatment are 
highlighted in yellow, while all other combinations exhibited significant decreases. The 
concentrations for each extract are recorded in micrograms of original leaf powder per 
milliliter [µg/mL].  
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viability (Table 5B) compared to subfraction 3 alone (with a treatment concentration of 100 
µg/mL after 24 hours). Therefore, these treatment combinations would not be used over some 
of their individual subfraction constituents alone. 
Despite these outliers, Table 5 shows that most treatment combinations outperformed 
their subfraction constituents alone. As mentioned previously, Table 5A supports a temporal 
effect on HeLa cell viability after treatment with subfraction combinations. There were no 
subfraction combinations that outperformed individual subfraction constituents at a 24 hour 
time point. Yet, several subfraction combinations significantly reduced HeLa cell viability 
when compared to individual subfraction constituents at a 48 hour time point. Looking at the 
collection of SiHa data (Table 5B), we can see that most treatment combinations applied to 
SiHa cells are able to further decrease cell viability compared to any individual subfraction 
constituents. This is in line with the results from Figure 6; results from Figure 6 indicate that 
individual subfractions applied to SiHa cells typically increased cell viability, so cell viability 
reductions from the combinations are likely to be significant compared to the cell viability 
increases of single subfractions.  
 
3.4 Potential Anticancer Molecular Mechanisms Altered by Subfraction Treatment 
 Results from our MTT assays support our hypothesis that HPLC-isolated subfractions 
from ethanolic M. oleifera leaf extracts would exhibit anticancer effects, but the MTT data 
cannot explain how or why HeLa and SiHa cervical cancer cell viability is decreasing. One 
possibility is that these subfractions are altering apoptotic pathways inside the cancer cells, 
which could account for the observed decrease in cell viability. While the NF-κB pathway 
has been linked to increased cancer cell growth, metastasis, and proliferation, as well as 
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increased proliferation of immune cells and their subsequent inflammatory responses, it is 
also associated with inducing apoptosis through induction of the pro-apoptotic protein, Bax. 
Consequently, we hypothesized that subfraction treatments might be altering the NF-κB 
pathway to induce apoptosis of these cervical cancer cell lines.  
 In order to determine if the NF-κB pathway was changing in response to subfraction 
treatment, we applied subfraction treatments at a concentration of 100 µg/mL to HeLa cells 
for 24 hours. Following the 24 hour incubation, the media was removed, the cells were lysed 
using a detergent buffer, and cell lysates were collected for Western blot analysis. Levels of 
phosphorylated NF-κB (p65) and total NF-κB were determined by immunoblotting, and the 
proteins were compared back to mock-treated negative control as shown in Figure 7. 
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Figure 7. Subfraction Effects on NF-κB Expression and Activation in HeLa Cells. HeLa 
cervical cancer cells were treated with ethanolic M. oleifera leaf extract (W) or an individual 
subfraction (2-8) for 24 hours. Cell lysates were collected and p-NF-κB and Total NF-κB 
protein expressions were determined via Western blotting. Representative images from bands 
subjected to Western blot analysis are shown (A). Protein levels were normalized to β-actin 
and then compared to the mock negative control. The concentrations for each extract are 
recorded in micrograms of original leaf powder per milliliter [µg/mL]. The data shown are an 
average of three experiments ± standard error. Asterisks indicate a significant change in 
protein levels compared to the negative control (P = <0.05) using two-tailed Student’s t-tests. 
A 
B 
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Figure 7B did not show any significant changes in NF-κB protein expression, 
although there might be a slight, but insignificant, decrease in p-NF-κB and Total NF-κB 
protein levels with subfractions 4, 5, 6, and 7. The data might also be indicating a slight, but 
insignificant, increase in p-NF-κB and Total NF-κB protein levels after treatment with whole 
extract (W) and subfraction 2. 
While the results from Figure 7 were not conclusive in showing NF-κB protein 
expression was being altered, we decided to further investigate the alteration of the NF-κB 
pathway by looking at two downstream proteins, Bax and Bcl-xL. These proteins have an 
antagonistic relationship where Bax induces apoptosis through mitochondrial stress, while 
Bcl-xL inhibits these apoptotic processes. Based on our previous data, we expected the 
Western immunoblotting data in Figure 8 to show the subfractions decreasing Bcl-xL levels 
(the inhibitor of apoptosis) and increasing Bax protein levels. 
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Figure 8. Subfraction Effects on Bax/Bcl-xL Expression in HeLa Cells. HeLa cervical 
cancer cells were treated with ethanolic M. oleifera leaf extract (W) or an individual 
subfraction (2-8) for 24 hours. Cell lysates were collected and Bax and Bcl-xL protein 
expression was determined via Western blotting. Representative images from bands subjected 
to Western blot analysis are shown (A). Protein levels were normalized to β-actin and then 
compared to the mock negative control. The concentrations for each extract are recorded in 
micrograms of original leaf powder per milliliter [µg/mL]. The data shown are an average of 
three experiments ± standard error. Asterisks indicate a significant change in protein levels as 
compared to the negative control (P = <0.05) using two-tailed Student’s t-tests. 
B 
A 
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Similar to the previous NF-κB Western blot data, we did not see great changes in Bax 
or Bcl-xL protein levels. The two exceptions to this were the significant decrease in Bax after 
treatment with subfraction 6 and the significant decrease in Bcl-xL in subfraction 7. 
Interestingly, the whole extract and subfraction 2 may increase Bax protein levels, which 
could be a sign of increased apoptosis from those treatments. In general, subfractions 2-8 did 
show increased levels of Bax while simultaneously exhibiting lower levels of Bcl-xL, which 
further supports our hypothesis that these subfraction treatments are increasing apoptosis in 
HeLa cells. 
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Chapter Four 
4. Discussion and Conclusions 
 While there are numerous applications of the medicinal plant, Moringa oleifera, the 
data presented in our study highlights the therapeutic potential of HPLC-separated leaf 
extracts in controlling inflammation and treating some types of cancer. HPLC separation of 
an ethanolic M. oleifera leaf extract generated 8 chemically unique subfractions, several of 
which had potent anti-inflammatory and anticancer properties associated with them. While 
most of these subfractions were able to alter inflammatory cytokine levels, subfractions 4, 5, 
6, 7, and 8 were able to significantly reduce the secretion of IL-6 and TNFα from THP-1 
cells in a lipopolysaccharide (LPS)-induced model of inflammation. Additionally, a handful 
of these HPLC-isolated subfractions were able to significantly reduce the cell viability of 
HeLa and SiHa cervical cancer cells. Furthermore, cervical cancer cell viability markedly 
decreased when treated with combinations of subfractions 2, 3, 5, 7, and 8, and a general 
temporal effect was observed when subfractions were applied for extended durations. These 
anti-proliferative effects of the subfractions on these cancer cell lines may tentatively be 
explained by alterations of the NF-κB pathway post treatment. While not statistically 
significant, treatment with some of the subfractions indicated a potential decrease in the 
expression of phosphorylated and total NF-κB protein. Western blot analysis also indicated 
that some subfraction treated cells produced an imbalanced ratio of pro-apoptotic Bax 
proteins compared to the antagonistic Bcl-xL protein.  
Based on our results, we believe that these HPLC-isolated subfractions have 
therapeutic potential to control dysregulated inflammatory processes that can contribute to 
tumor progression, as well as directly decrease the cell viability of some cancerous cell types. 
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Finally, we believe these subfractions, separated from the whole ethanolic M. oleifera leaf 
extract, can be further investigated through analytical techniques to identify the chemical 
constituents responsible for the extract’s bioactivity.   
 Several research groups have reported that M. oleifera extracts are able to reduce 
inflammation and induce deleterious effects on cancer cells in vitro. Of course, these extracts 
can be prepared many ways, but even relatively simple extraction techniques and solvents 
can yield potent M. oleifera products. For example, one research group was able to 
characterize several potent anti-inflammatory compounds from an aqueous M. oleifera 
extract, and they even reported that many of these compounds had naturally been converted 
into stable bioactive forms (Waterman et al., 2014). They found that naturally myrosinase in 
their extract was converting moringa glucosinolates into isothiocyanates, which are “shelf” 
stable and potentially useful for nutraceutical development. Using an in vitro murine 
neoplastic mononuclear cell model of LPS-induced inflammation, these extracted 
isothiocyanates were shown to substantially alter inflammatory cytokine gene expression 
(including iNOS, IL-1β, IL-6, and TNFα) (Waterman et al., 2014). 
 Other research groups have looked at comparable M. oleifera products and found 
various anticancer compounds are prevalent in extracts made from the leaves and bark of the 
plant. Even more promising, many of these extracts appear to be effective at killing or 
inhibiting cell growth across different cancerous cell lines (Al-Asmari et al., 2015). Extract 
made from both the leaves and bark were able to drastically reduce MDA-MB-231 breast 
cancer cell viability, as well as significantly reduce HCT-8 colon cancer cell viability, colony 
formation, and cell motility (Al-Asmari et al., 2015). Isothiocyanates were also found in 
these M. oleifera leaf and bark extracts, as reported by the previously mentioned research 
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group, and were believed to be exhibiting anticancer properties along with several other 
known anticancer compounds like eugenol and D-allose (Al-Asmari et al., 2015). 
In addition to these recent reports, previous studies in our labs have shown that the 
ethanolic M. oleifera leaf extract can modulate the secretion of inflammatory cytokines, 
decrease cervical cancer cell viability, and alter proliferative pathways inside some cervical 
cancer cell lines. Therefore, to further investigate these therapeutic properties, we decided to 
separate the complex whole extract using HPLC and isolate the bioactive compounds in 
distinct subfractions. As seen in Figure 1, we divided the effluent mixture into 8 subfractions 
using natural divisions in the chromatograph. There were two discernable regions of 
detectable analytes in our chromatograph, an early region from 7 to 17 minutes and a later 
region between 34 and 48 minutes. While these regions were initially useful for dividing the 
whole extract into manageable subfractions, it is worth noting that the gap in analyte peaks 
between 18 and 33 minutes is most likely due to the limits of the detector and not lack of 
discernable analytes. As several studies have identified a wide range of phytochemicals in M. 
oleifera leaf extracts, it is reasonable to postulate that using a shorter wavelength channel    
(< 330 nm) for the detector could have produced more analyte peaks in this region of the 
chromatograph. In fact, one our most prominent subfractions, Subfraction 5, was isolated 
from this region of the HPLC run, indicating there are bioactive compounds not being 
detected from the 330 nm channel.  
 The time frame of subfraction isolation is indicative of the types of chemical 
constituents that can be expected to be found inside each separated grouping due to our 
unique 2-solvent elution. In the beginning of the run, the primary solvent is acidified water 
which most effectively carries polar inorganic compounds through the column. However, 
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during the course of the HPLC run, the solvent system slowly incorporates acidified 
acetonitrile into the elution mixture until it is only organic solvent after 40 minutes of run 
time. This 2 step elution system not only helps to efficiently separate the whole ethanolic 
extract, but it also provides reasonable insights to the types of bioactive compounds that 
might be identified in the subfractions. For example, both quercetin and kaempferol are 
known phytoconstituents in M. oleifera extracts and both are polar/protic organic 
compounds. Therefore, it is likely that these bioactive compounds would be isolated from a 
subfraction with a mix of water and acetonitrile, where polar water molecules could help 
elute the polar organic analytes that aren’t completely miscible with the aprotic acetonitrile.  
 Dysregulated inflammatory responses from the immune system can lead to self-
perpetuated cell signaling, increased immune cell recruitment, and subsequent activation of 
other localized immune cells. While inflammatory positive feedback loops may be 
advantageous for mounting an effective immune response in the early stages of an infection, 
this prolonged cell signaling, and immune response can have damaging effects (both locally 
and systemically) when it becomes chronic. Chronic inflammation is a contributing factor to 
a plethora of diseases and more recently has been identified as a hallmark of cancer 
pathogenesis. The increased immune cell signaling in chronically inflamed tissues can lead to 
angiogenesis which provides additional nutrients to a growing tumor. Further activation of 
these immune cells leads to the production of reactive oxygen species, which can cause 
additional damage to DNA and lead to multiple cancer cell mutations. Interestingly, data 
from our experiments suggest that several of our subfractions could have therapeutic effects 
in inflammatory diseases due to their ability to decrease immune cell secretions of pro-
inflammatory cytokines. As seen in Figures 2A and 2B, THP-1 monocytes pretreated with M. 
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oleifera subfractions 4, 5, 6, 7, and 8 before LPS challenge significantly reduced levels of the 
inflammatory cytokines, IL-6 and TNFα. When only looking at IL-6 data (Figure 2A), it is 
interesting to note that our subfractions were able to significantly reduce the secretion of this 
inflammatory cytokine at markedly lower concentrations than the ethanolic whole extract 
from which they were derived. The subfractions were applied at a concentration of 200 
µg/mL, versus the whole extract (W) which was applied at a concentration of 200,000 
µg/mL, or three orders of magnitude higher. While these subfractions were clearly effective 
at reducing IL-6 secretion at concentrations of 200 µg/mL, none of the extracts were able to 
decrease cytokine secretion to levels comparable with our mock challenged (negative 
control) except for the whole extract at 200,000 µg/mL.  
 The results from the TNF data (Figure 2B) were even more auspicious, as they 
showed that pretreatment with subfractions 3, 5, 7, and 8 could significantly reduce levels of 
TNFα at low concentrations of 100 µg/mL. Equally promising, all tested subfractions (2-8) 
significantly reduced levels of secreted TNFα when treated at concentrations of 200 µg/mL. 
However, similar to the IL-6 data, pretreatment with the ethanolic whole extract was the only 
treatment type that showed results comparable to mock. Although, it is worth mentioning that 
treatment with subfractions 7 and 8 at 100 µg/mL were producing comparable effects to W at 
100,000 µg/mL. 
Overall, our data indicate that pretreatment with HPLC-isolated subfractions is able to 
considerably inhibit the secretion of IL-6 and TNFα inflammatory cytokines from THP-1 
monocytes in an LPS-challenge model. Both of these inflammatory cytokines are used as 
biomarkers for inflammation, and their relative abundance has been directly linked to the 
severity of local inflammation (Bernecker et al., 2013; Del Giudice and Gangestad, 2018). 
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These immune signaling proteins accumulate in areas of tissue damage, where they stimulate 
a protective immune response and recruit immune cells like neutrophils and monocytes 
(which later differentiate into macrophages) (Del Giudice and Gangestad, 2018). Initially, the 
nonspecific inflammatory response triggered by these cytokines is helpful for clearing 
infections and containing local damage; however, as these immune responses become 
chronic and dysregulated, the presence of these cytokines can lead to excess tissue damage, 
swelling, pain, increased metabolic rates, and various other harmful side effects that can 
become systemic (Del Giudice and Gangestad, 2018). Thus, the capability of our 
subfractions to inhibit the secretion of these inflammatory cytokines could be useful in 
creating novel nutraceuticals for acute and chronic inflammatory conditions.  
That being said, our data cannot attest to the effects of the subfractions if they are 
applied to THP-1 cells after exposure to LPS. Although, there is at least one study that used 
an ethanolic extract (analogous to our whole M. oleifera extract) to treat CFA-induced 
arthritis in rats, in which they saw significant reductions in swelling and other signs of 
inflammation post-challenge (Mahdi et al., 2018). Additionally, while our THP-1 monocytes 
behave comparably to normal human monocytes, they are cancerous in nature being a 
monocytic leukemia cell line. While there are numerous studies using THP-1 monocytes as 
analogues for human immune cells in LPS-induced models of inflammation, it cannot be 
ruled out that the immunomodulatory effects seen in our data may be attributable to the M. 
oleifera extracts altering, or potentially killing off, these cells. While cell viability assays 
were not performed in tandem with our experiments, it seems unlikely that cell death was the 
principle factor for the decreasing cytokine levels. During the ELISA supernatant collection 
process, pellets of cells were often observed after centrifugation, and many other cells were 
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seen to be adherent on the plate after challenge with LPS. The increased propagation of cells 
in our dishes and supernatant, along with changes in media conditions, is highly indicative of 
metabolically active cells being present over the course of the experiments.  
 The immunomodulatory properties of our extracts offer promising therapeutic 
potential for inflammatory diseases, but it is also conceivable that these properties could be 
impactful in a tumor microenvironment, where immune cell signaling is often chronic and 
supplemental to tumor progression. There is also a growing body of evidence that indicates 
M. oleifera products may have anticancer properties associated with them, and several 
studies have successfully isolated and identified known anticancer compounds from their 
extracts. As discussed earlier, a couple of research groups have found a class of anticancer 
compounds known to induced apoptosis in M. oleifera extracts called isothiocyanates (Al-
Asmari et al., 2015; Giacoppo et al., 2017). Other research groups have identified and 
pursued follow-up studies with two potent antiproliferative compounds, quercetin and 
kaempferol, both of which have shown to be efficacious across several cell lines (Li et al., 
2016; Rajendran et al., 2014). 
Prior studies in our lab have generated data that indicates ethanolic M. oleifera extract 
has in vitro anticancer effects in a cervical cancer cell model. Therefore, we predicted that 
some our HPLC-isolated subfractions, which were derived from the ethanolic whole leaf 
extract, would also exhibit anticancer effects when applied to cervical cancer cells. Indeed, 
our results did show that some subfraction treatments could reduce HeLa and SiHa cervical 
cancer cell viability in both a concentration and time dependent manner. Furthermore, 
combination treatments with our most potent subfractions were able to induce significant 
decreases in cervical cancer cell viability.  
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 Initially, we wanted to see if any of these subfractions could significantly reduce 
cervical cancer cell viability in a comparable way to the ethanolic whole leaf extract from 
which they were derived (data presented in Figures 3 and 4). We chose to use two cervical 
cancer cell lines, HeLa and SiHa, to get a broader understanding of any potential anticancer 
effects, since cancerous cells are known to be highly variable (even in the same types of 
cancer). While both cell lines are classified as cancerous cells from the cervix, HeLa cells 
have been classified as a rare form of adenocarcinoma, while SiHa cells are classified as a 
squamous cell carcinoma (Rahbari et al., 2009; Meissner, 1999). Additionally, the strain of 
HPV that infected these cells and led to subsequent cancerous mutations was also different, 
with HeLa cells containing HPV-18 DNA and SiHa cells containing HPV-16 DNA (Ristriani 
et al., 2009). Both of these strains of HPV are indicated as “high risk” strains due to their 
ability to express two viral oncoproteins, E6 and E7 (Nominé et al., 2006). In particular, this 
E6 oncoprotein is known to ubiquinate tumor suppressor p53, ultimately resulting in its 
degradation and leading to tumorigenesis (Nominé et al., 2006; Ristriani et al., 2009). 
Previous experiment from our labs, also using whole M. oleifera extracts, has 
revealed that these two cell lines respond quite differently to treatment with the same extract 
and treatment concentrations; thus, comparing the results between these two cell lines might 
help us gauge the potency of our subfractions across similar cell lines of the same type of 
cancer. Ultimately, we did observe subfractions eliciting different results in one cell line 
compared to the other, but both cell types did show some degree of susceptibility to treatment 
with our HPLC-isolated subfractions.  
 Looking at the data for the HeLa cells (Figures 3A and 3B), we can see that treatment 
with some subfractions significantly reduced cancer cell viability. Subfraction 6 was the only 
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subfraction to not induce any significant changes after 48 hours.  It is worth noting that more 
subfractions exhibited a significant impact on HeLa cell viability after 48 hours (3B) 
compared to the 24 hour time point (3A). We believe this observation is indicative of a 
temporal relationship between cell viability and subfraction treatments. In addition to this 
temporal relationship, we also observed what appears to be a general decrease in cell 
viability with an increase in treatment concentration. However, one notable exception to this 
would be subfraction 3, where the 100 µg/mL concentration decreased cell viability more 
than the 200 µg/mL at both the 24 and 48 hour time points. While cell viability did not 
change significantly with whole extract (W) treatment at concentrations of 100 or 200 
µg/mL, we observed the most significant changes to HeLa cell viability when W was applied 
at concentrations of 100,000 and 200,000 µg/mL. Excluding treatment with the highest 
concentrations of W, we can say that HeLa cell viability was most significantly reduced by 
subfractions 2, 3, 5, 7, and 8, with subfraction 5 being the most prominent subfraction to 
reduce cell viability.  
 The SiHa cell viability data (shown in Figures 4A and 4B) is noticeably different than 
the HeLa cell viability, as there were several subfractions that appeared to significantly 
increase the cancer cell viability. Subfractions 2, 3, 4, and 6 all significantly increased cell 
viability by 48 hours, and while some subfractions (3, 5, and 8) initially decreased cell 
viability at the 24 hour time point, these reductions were no longer significant at the 48 hour 
time point (Figure 4B). In fact, the general temporal trend we observed in the HeLa cell 
viability data no longer appears in the SiHa cell viability data. The effects from most of our 
subfraction treatments applied to SiHa cells seems to either stagnate after 24 hours or cause 
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an undesirable increase in SiHa cell viability from the 24 hour time point to the 48 hour time 
point.  
Clearly, our subfraction data is comparable in some ways to our labs’ previously 
published data, where some treatments that work for one cancer cell line may not work for 
another. Tentatively, a couple of explanations for why the SiHa cell viability might be 
increasing over time could involve the cells degrading harmful bioactive compounds in the 
extracts, using compounds in the extracts for nourishment, or even a combination of both. If 
all bioactive compounds have been degraded by 24 hours, we wouldn’t expect to see 
noticeable differences in cell viability after 48 hours. Additionally, if the cancerous cells 
have neutralized or degraded the bioactive compounds by 24 hours, their ensuing 
proliferation would be uninhibited and potentially increased by other extract constituents, 
leading to increased cell viability at the 48 hour time point. Other researchers have also 
commented on the potential negative effects of phytates or other antinutrients commonly 
found in M. oleifera extracts; these phytoconstituents can obstruct the absorption or alter the 
activity of other bioactive compounds (Mahdi et al., 2018). 
 So far, most of our cancer cell viability analysis has focused solely on the effect of 
individual HPLC-isolated subfractions, but it is interesting to compare the effects of the 
subfractions to those of the whole extract. In HeLa cells, treatment with the lower 
concentrations of W (100 and 200 µg/mL) had minimal impacts on cell viability. However, 
SiHa cell viability actually increased significantly when the lower concentrations of W were 
applied. These observations further attest to the greater potency of the subfractions, where 
our subfractions were efficacious at low concentrations but the whole extract was not. 
Conversely, when higher concentrations of the whole extract (100,000 and 200,000 µg/mL) 
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were applied to the cancer cells, both cell types had strikingly significant reductions in cell 
viability. As it was observed, both cell types exhibited temporal and dose-dependent 
relationships between cancer cell viability and whole extract application. Overall, the 
reduction in cancer cell viability from the 200,000 µg/mL concentration of W was noticeable, 
but it might not offer a viable therapeutic options due to impractical application volumes this 
concentration would require.  
 As a whole, we did observe underlying anticancer effects from our cervical cancer 
MTT assays, although none of our subfractions produced exceptional cell viability reductions 
on their own. Therefore, we decided to test combinations of the most effective subfractions to 
determine if they might have synergistic effects with one another. Thus, we tested 
combinations of two and three distinctive subfractions to determine if complimentary 
bioactive compounds could more effectively decrease cell viability when applied to HeLa 
(Figure 5) and SiHa (Figure 6) cervical cancer cells. Overall, we noticed considerably lower 
reductions in cell viability when subfractions were applied in combination than on their own; 
additionally, the previously mentioned temporal and dose-dependent trends were further 
elucidated by these results.  
 Focusing on the data for subfraction combinations being applied to HeLa cells 
(Figure 5), our results further support a temporal and dose-dependent relationship between 
cancer cell viability and subfraction treatment. Additionally, we see that most combinations 
of subfractions seemed to further decrease HeLa cell viability, with the three subfraction 
combinations showing the most striking differences (indicated by the darker shades of blue). 
However, several subfraction combinations containing subfraction 5 do not appear 
statistically different than subfraction 5 alone. Ultimately, this data seems to indicate that 
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most of the subfractions have synergistic effect with one another, except for subfraction 5, 
which appears to be most effective when applied alone or in combination with 2 other 
subfractions.  
 Treatment with subfraction combinations in SiHa cells (Figure 6) resulted in 
pronounced reductions in cancer cell viability, which was not commonly observed with 
individual subfraction treatments. As stated previously, several of the individual subfractions 
applied to SiHa cells resulted in significant increases in cancer cell viability; however, none 
of the subfraction combination treatments increased cell viability. In fact, SiHa cell viability 
was significantly decreased with most combination treatments at the 24 hour time point, and 
all subfraction combinations caused a significant reduction in SiHa cell viability when 
applied for 48 hours. This data also suggests there may be a slight temporal effect when 
applying the subfraction combinations, but there does not seem to be an obvious difference 
between the 24 hour and 48 hour data. In every case, increasing the subfraction concentration 
resulted in a subsequent decrease in SiHa cell viability, which is indicative of a strong 
negative correlation between treatment concentration and cancer cell viability. By and large, 
this SiHa cell viability heat map indicates that many of these subfractions have synergistic 
effects when applied together, including several of the combinations containing subfraction 5 
(contrary to the HeLa cell results).    
 After examining the general trends in the cervical cancer cell viability heat map, it is 
apparent that some combinations of subfractions have additive effects; yet, other 
combinations do not seem to noticeably change cell viability, and some may actually dampen 
the therapeutic effects of a single subfraction alone.  
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Therefore, we used a series of Student’s t-tests to determine if there were any 
significant differences between subfraction combination treatments and their individual 
subfraction components in reducing cell viability. The results of all of these t-tests can be 
seen in Tables 1 – 4. Clearly there were numerous comparisons to be made, but the most 
promising comparisons were those that showing significant changes in cell viability from 
treatment with subfraction combinations compared to their individual components. 
Subsequently, all of the combination treatments that significantly changed cell viability 
compared to the individual subfraction treatments alone were compiled into a condensed 
table, with HeLa cell data in Table 5A and SiHa cell data in Table 5B.  
 Looking at the HeLa cell viability data from Table 5A, we can see that most of the 
subfraction combination treatments did have some additional effects compared to their 
constitutive subfractions alone. Although, as mentioned previously, treatment with 
subfraction 5 alone seemed to be highly effective a reducing HeLa cell viability. Thus, the 
only significant reduction we see from a combination treatment, compared to treatment with 
subfraction 5 alone, was at the 48 hour time point with subfraction 2, 5, and 7 applied at 200 
µg/mL. Across the board, subfraction combination treatments only significantly reduced 
HeLa cell viability after 48 hours, which further falls in line with the previously noted 
temporal effect seen when treating HeLa cells. While observing synergistic effects between 
the combination treatments offers some additional therapeutic potential to these subfractions, 
the data seem to indicate subfraction 5 alone as an exemplary subfraction to begin chemical 
analysis and identify potential anticancer compounds from.  
 The SiHa cell viability data (from Table 5B) looks noticeably different than the HeLa 
cell viability data. Arguably, there are two prominent differences, the first being the lack of a 
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temporal effect. As Table 5B shows, a multitude of combinations treatments resulted in 
significant decreases compared to their individual constitutive subfractions at both the 24 
hour and 48 hour time points. Yet, this may not be too surprising considering that our heat 
map data (Figure 6) suggests that treatment concentration is far more important than 
treatment duration at reducing SiHa cell viability. The second distinct difference is that more 
subfractions appear to work synergistically to reduce cell viability, including combination 
treatments including subfraction 5, which was not the case when these combination 
treatments were applied to HeLa cells. Looking back at the heat map data, SiHa cells did not 
appear to be susceptible to individual subfraction treatments alone, with subfractions 3 & 5 
as a partial exception; however, several subfraction combination treatments were able to 
significantly reduce SiHa cell viability where their constitutive subfractions could not (as 
highlighted in Table 5B).  
 Considering all of the cell viability data together, several conclusions can be made for 
the therapeutic potential of our M. oleifera HPLC-isolated subfractions when applied to 
cervical cancer cells in vitro. First off, our data suggest that treatment efficacy depends on 
the cell type to which a subfraction is applied to. When looking at individual subfraction 
treatments (Figures 3 and 4), we can see that SiHa cells seem to be far more resistant to 
treatment than HeLa cells, which was previously noted in (Brown et al., 2015). While both 
cell lines originated from patients with cervical cancer, they have each acquired unique 
mutations during their cancerous development, which could drastically alter the way they 
respond to different treatments. Similarly, we know from the HPLC chromatograph (Figure 
1) that our subfractions have been thoroughly separated, and that each subfraction has its 
own unique chemical profile of various bioactive compounds. Therefore, due to the unique 
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nature of each cell line and subfraction, it is not surprising that the therapeutic potential of an 
individual subfraction might change even when applied to different cervical cancer cells (let 
alone cells from another type of cancer).  
 A second general conclusion we can make is that subfraction treatment efficacy is 
time-dependent. In both HeLa and SiHa cell lines, we observed that subfraction treatment 
further decreased cell viability over time, and these temporal effects particularly notable in 
the SiHa cell viability data (Figure 6). We also observed a prominent dose-dependent 
reduction in cell viability with the HeLa cell line, but this connection was not as evident in 
our results for the SiHa cell line. One possible explanation for this might be that a plateau 
effect was occurring, particularly with the combination treatments. As commented on 
previously, there appeared to be additional therapeutic synergy when combinations of 
subfractions were applied to the SiHa cells. So, it seems plausible that some of the 
combination constituents may be promoting SiHa cell death through similar mechanisms. 
Subsequently, we may be seeing a treatment plateau, where multiple subfractions are 
working in comparable ways to reduce SiHa cell viability; therefore, the resulting deleterious 
effects are more dependent on time rather than ample exposure to bioactive compounds. In 
other words, there are sufficient amounts of bioactive compounds to instigate SiHa cell 
death, but treatment time may be the limiting factor to see further reductions in cell viability.  
 While the cell viability assays show promising potential for our HPLC-isolated M. 
oleifera subfractions to treat some types of cervical cancer, it is important to consider the 
scope of our experimental results. Stated once more, our experiments have only looked at the 
effects of subfraction treatment when applied to cervical cancer cells, and even within 
different types of cervical cancer cell lines we observed varying treatment efficacy. Ergo, 
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these auspicious results are not directly applicable for treating other types of cancers without 
further investigation. Furthermore, it would be insightful to confirm that treatment with our 
subfractions does not cause pernicious effects in healthy cell types. There is a large body of 
research supporting the safety and efficacy of M. oleifera extracts, but supplemental cell 
viability assays on healthy cervical cells would be an important follow-up step before 
considering in vitro experiments. As a final counterpoint to our conclusions thus far, the 
presented cell viability data does not provide any insightful information as to how our 
subfraction treatments are affecting cancer cell viability. To help elucidate these mechanisms 
of action, we decided to investigate how known proliferative pathways may be altered with 
subfraction treatment using a series of Western blotting techniques.  
 One such pathway is the NF-κB pathway, which is a key pathway in regulating both 
cell survivability as well inflammatory responses. Activation of the NF-κB protein complex 
leads to the upregulation of several inflammatory and proliferative genes, and several 
cancerous cell lines are known to have dysregulated NF-κB pathways which enhances their 
survival and proliferative capabilities. Additionally, the upregulation of inflammatory genes 
from this pathway can promote tumor progression by creating chronically inflamed tumor 
microenvironments, which can further foster the proliferation, survivability, migration, and 
inevitable metastasis of the cancerous cells (Coussens and Werb, 2002). Taking into account 
the broad implications this pathway has on cancer development, we used Western blotting 
techniques to determine if our subfractions might be altering the levels of phosphorylated 
NF-κB (the transcriptionally active form) or total NF-κB in our HeLa cervical cancer cells.  
 Reviewing the Western blot data for the NF-κB proteins did not show any significant 
changes in expression levels. However, upon further examination there are some potential 
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differences between the treatments. Protein expression could potentially be increasing with 
whole extract and subfraction 2 treatments, while treating HeLa cells with subfractions 4, 5, 
6, and 7 could be causing subtle differences in expression levels. Subfractions 4, 5, and 6 
appear to have steady levels of the active phosphorylated NF-κB, but these treatments may 
be reducing the total amount of NF-κB protein inside the cancer cells. Although this 
reduction in total NF-κB protein is not large, it could be the precursor of more significant and 
impactful changes given higher treatment concentrations or increased treatment time. 
Treatment with subfraction 7 may be having similar effects, where total NF-κB levels may be 
declining, and even phosphorylated NF-κB may be decreasing as well. Yet, this data is hard 
to discern due to the large range in uncertainty, so additional Western blot analysis would be 
required to make more definitive claims. 
 Despite our NF-κB protein expression data being somewhat inconclusive, it is worth 
considering that the aforementioned subtle changes are in line with our cell viability data. 
Our cell viability data for treating HeLa cells with individual subfractions over 24 hours 
(Figure 3A) did not show much change in the cancer cell viability. The only prominent 
decreases in HeLa cell viability at this treatment concentration and time point occurred with 
subfraction 5 treatment, which might also be the treatment that caused the most reduction in 
total NF-κB expression levels. Due to the ambiguous Western blot data for NF-κB 
expression, future experiments could be executed at a 48 hour time point to give ample time 
for expression levels to change in response to subfraction treatment (presumably at both the 
100 and 200 µg/mL concentrations). Since our investigation into subfraction treatments 
directly altering NF-κB protein expression was inconclusive, we decided to look at other 
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proteins commonly linked to cell death mechanisms that our HPLC-isolated M. oleifera 
subfractions may be altering.  
A critical hallmark in cancerous cell progression is the capacity for cells to evade 
apoptosis (Hanahan and Weinberg, 2011). Apoptosis, or programmed cell death, is a highly 
regulated process in healthy cells that insures old or damaged cells are removed without 
damaging healthy cells and provoking inflammatory responses (Pucci et al., 2000). Taking 
this into consideration, it is not only desirable for cancer treatments to kill abnormal tumor 
cells, but also induce to apoptosis in the cancerous cells which will mitigate tissue damage 
and additional local inflammation. Two protein groups known to tightly regulate apoptosis 
are Bax, a pro-apoptotic protein, and the Bcl-2 family proteins (including Bcl-xL), that act 
antagonistically to Bax and prevent apoptosis. Interestingly, some researchers have reported 
that the consumption of M. oleifera products is able to induce colon cancer cell death by 
upregulating the ratio of Bax to Bcl family proteins (Kraiphet et al., 2018). Subsequently, we 
decided to see if our subfraction treatments might be altering the ratio of Bax to Bcl-xL 
proteins in our HeLa cervical cancer cell model, and linking some of the aforementioned 
decrease in HeLa cell viability to apoptotic pathways.  
Similar to our results on NF-κB protein expression, Western blot analysis for Bax and 
Bcl-xL proteins isolated from HeLa cells treated with 100 µg/mL of subfractions over 24 
hours did not yield many statistically significant changes in protein expression. Although, 
due to the interconnected and antagonistic nature of these two proteins, it may be more 
important to consider how the expression ratio of these two proteins changed rather than how 
each individual protein’s expression changed. It has been shown that although Bax and Bcl-
xL act antagonistically to each other, Bax is dependent on Bcl-xL to efficiently translocate to 
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the mitochondrial outer membrane, where it can initiate endogenous apoptosis (Renault et al., 
2017). Cancer cells are often known to overexpress Bcl-xL proteins, so decreasing 
expression of Bcl-xL in these cells is certainly key in reinstating standard endogenous 
apoptosis (Renault et al., 2017). Yet, this recent study also indicates that having some Bcl-xL 
proteins present allows for more effective recruitment of Bax molecules to come together and 
form pores in the mitochondrial outer membrane (Renault et al., 2017). Therefore, an 
expression ratio of these proteins shifted towards Bax expression, but not completely lacking 
in Bcl-xL expression, may be the most effective at restoring endogenous apoptosis to cancer 
cells (assuming there are no additional mutations in Bax rendering it ineffective). 
With that in mind, treatment using subfraction 2 may have drastically altered this 
ratio, in which we see increased levels of pro-apoptotic Bax and decreased levels of anti-
apoptotic Bcl-xL. This imbalanced ratio between Bax and Bcl-xL protein expression is 
observable to some extent from treatment with subfractions 3, 4, 5, 7, and 8, albeit not as 
drastic as subfraction 2. Further support that our subfraction treatments might be altering the 
ratio of Bax/Bcl-xL proteins comes from looking back at the cell viability data in Figure 3A. 
There does appear to be some overlapping effects in our cell viability data and apoptotic 
protein data. Subfraction 2 did significantly reduce HeLa cell viability, and our Western blot 
analysis showed it created a large imbalance in the Bax/Bcl-xL ratio. Additionally, treatment 
with subfractions 3, 5, and 8 also significantly reduced HeLa cell viability, and potentially 
shifted Bax/Bcl-xL protein expression towards pro-apoptotic Bax proteins. Nonetheless, the 
small experimental sample size (n = 3) and relatively large variation between experimental 
trials makes it hard to definitively conclude that these subfractions are favorably altering the 
Bax/Bcl-xL balance towards the pro-apoptotic Bax protein.  
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While there were not many statistically significant changes in Bax or Bcl-xL protein 
expression from our Western blot analysis, two subfraction treatments did significantly alter 
the expression of these antagonistic proteins. Treatment with subfraction 6 actually 
significantly reduced the expression pro-apoptotic Bax, but also appeared to reduce the 
expression of anti-apoptotic Bcl-xL. Looking back at the cell viability data from Figure 3A 
again, we can see that this subfraction treatment did not cause any significant changes in cell 
viability. Thus it stands to reason that while this subfraction is lowering Bax and Bcl-xL 
protein expression, it’s likely not altering the balance between the two proteins. Subfraction 7 
treatment also significantly decreased anti-apoptotic Bcl-xL expression. Unfortunately, there 
was a lot of variation in our Western blot analysis of subfraction 7’s effect on Bax protein 
expression, so there may not be a large imbalance between Bax expression and Bcl-xL 
expression.  
As mentioned within the discussion of our NF-κB Western blot analysis, we might 
observe more significant changes in Bax/Bcl-xL expression if we increase treatment 
concentrations or allow additional time for cumulative effects on intracellular apoptotic 
protein expression. Another limitation to our study was that we only looked at one cervical 
cancer cell line thus far (HeLa cells), but future experiments could examine changes in other 
cervical cancer cell lines like SiHa cells. While our Western blot data is not entirely 
conclusive, we did see that our subfractions have the potential to alter apoptotic protein 
expression in HeLa cells. Treatment with subfraction 7 caused a significant reduction in 
expression of the anti-apoptotic protein, Bcl-xL, which warrants further investigation. 
Conversely, treatment with subfraction 2 appeared to drastically increase the expression of 
pro-apoptotic Bax, although increase was not statistically significant. While no Western blot 
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analysis was done on subfraction combination treatments, it is interesting to think about the 
therapeutic potential of combining the observed effects of subfractions 2 and 7, where there 
might be a significant increase in Bax and a significant decrease in Bcl-xL. This potential is 
underpinned by the results of Figure 5, which shows this subfraction combination treatment 
did significantly reduce HeLa cell viability. Overall, our Western blot analysis of apoptotic 
proteins seems to indicate that some of our HPLC-isolated M. oleifera subfractions may be 
inducing apoptosis in HeLa cancer cells, but further investigation is required.  
In summary, the results from this project suggest that our HPLC-isolated subfractions 
partitioned from an ethanolic M. oleifera leaf extract have therapeutic properties that could 
be developed into treatments for inflammatory disorders and some types of cancers. We saw 
that pretreatment with our HPLC-isolated subfractions was able to significantly decrease the 
secretion of IL-6 and TNFα inflammatory cytokines from THP-1 monocytes in an LPS-
challenge model. Several of our HPLC-isolated subfractions were able to reduce HeLa and 
SiHa cervical cancer cell viability in a dose and time-dependent manner, and they were 
efficacious at applied concentrations much lower than the original whole extract from which 
they were derived. Additionally, we observed synergistic effects when combining our 
subfractions treatments in groups of two or three, which resulted in substantial reductions to 
HeLa and SiHa cell viability. While our Western blot data was somewhat inconclusive, there 
were underlying favorable trends in the protein expression ratios of Bax/Bcl-xL, which could 
be indicating that our subfractions have the potential to induce apoptosis in HeLa cancer 
cells. As a final note, our HPLC chromatograph did reveal that our subfractions contained 
distinct chemical profiles, and we hope to use this knowledge (coupled with analytical 
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chemistry techniques) to identify the bioactive compounds in these subfractions that hold 
therapeutic potential. 
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